{"id": "k9B2zgsAAAAJ", "citedby": 51890, "citedby5y": 30081, "hindex": 91, "hindex5y": 72, "i10index": 242, "i10index5y": 193, "coauthors": [{"id": "2jTP-TEAAAAJ", "name": "Torsten Nielsen", "affiliation": "Professor of Pathology, University of British Columbia"}, {"id": "4rCtnzEAAAAJ", "name": "Elaine Mardis", "affiliation": "Ohio State University"}, {"id": "hfX05q8AAAAJ", "name": "Daniel F. Hayes", "affiliation": "professor internal medicine"}, {"id": "qJ3MPJAAAAAJ", "name": "Maggie Cheang", "affiliation": "THE INSTITUTE OF CANCER RESEARCH"}, {"id": "lGMQTBQAAAAJ", "name": "Joel Parker", "affiliation": "University of North Carolina at Chapel Hill"}, {"id": "QPftnyEAAAAJ", "name": "George Thomas Budd", "affiliation": ""}, {"id": "JCqzqUMAAAAJ", "name": "Charles M. Perou", "affiliation": "University of North Carolina at Chapel Hill"}, {"id": "c7kDOR4AAAAJ", "name": "Marcom", "affiliation": "Professor of Medicine, Duke University"}, {"id": "TBLm_eUAAAAJ", "name": "Massimo Cristofanilli", "affiliation": "Northwestern University"}, {"id": "YhCgxOAAAAAJ", "name": "Stephen KL Chia", "affiliation": "Medical Oncology, British Columbia Cancer Agency"}, {"id": "3AGo6DUAAAAJ", "name": "Kathleen I. Pritchard", "affiliation": "Professor, Division of Medical Oncology, University of Toronto"}, {"id": "cKR4JoEAAAAJ", "name": "William (Bill) Barry", "affiliation": "Senior Reseach Scientist, Rho, Inc"}, {"id": "rY8u8xkAAAAJ", "name": "Donald Berry", "affiliation": "professor of biostatistics, m.d. anderson cancer center"}, {"id": "g9p6auUAAAAJ", "name": "Feng Gao", "affiliation": "Washington University School of Medicine"}, {"id": "UR2BQW8AAAAJ", "name": "Antonio C. Wolff, MD, FACP, FASCO", "affiliation": "Professor of Oncology, Johns Hopkins University"}, {"id": "2_XMQ_oAAAAJ", "name": "Obi L. Griffith", "affiliation": "Associate Professor, Washington University School of Medicine"}, {"id": "zmreEcYAAAAJ", "name": "James Reuben", "affiliation": "Professor, University of Texas MD Anderson Cancer Center"}, {"id": "fcIQQ3oAAAAJ", "name": "Malachi Griffith", "affiliation": "Assistant Professor, Medicine, Washington University School of Medicine"}, {"id": "YaGbE_EAAAAJ", "name": "Hao Guo", "affiliation": "Department of Biostatsitics and Computational Biology, Dana-Farber Cancer Institute"}, {"id": "MtoBeRAAAAAJ", "name": "Ron Bose", "affiliation": "Associate Professor of Oncology, Washington University School of Medicine"}], "name": "Matthew Ellis", "affiliation": "Professor of Medicine and Cellular and Molecular Biology", "interests": ["breast cancer", "cancer genomics", "cancer proteomics"], "cites_per_year": {"2002": 252, "2003": 401, "2004": 476, "2005": 608, "2006": 874, "2007": 1039, "2008": 1257, "2009": 1429, "2010": 1746, "2011": 2193, "2012": 2641, "2013": 3666, "2014": 4193, "2015": 4758, "2016": 5325, "2017": 5693, "2018": 5657, "2019": 6058, "2020": 2443}, "publications": [{"bib": {"title": "Comprehensive molecular portraits of human breast tumours", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rOcdG6UcVlcC", "citedby": "6216"}, {"bib": {"title": "Circulating tumor cells, disease progression, and survival in metastatic breast cancer", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zA6iFVUQeVQC", "citedby": "4060"}, {"bib": {"title": "Supervised risk predictor of breast cancer based on intrinsic subtypes", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u_35RYKgDlwC", "citedby": "3238"}, {"bib": {"title": "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dfsIfKJdRG4C", "citedby": "2230"}, {"bib": {"title": "The molecular portraits of breast tumors are conserved across microarray platforms", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4OULZ7Gr8RgC", "citedby": "1532"}, {"bib": {"title": "Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bFI3QPDXJZMC", "citedby": "1329"}, {"bib": {"title": "Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1\u2013and/or ErbB-2\u2013positive, estrogen receptor\u2013positive primary breast cancer: evidence from a \u2026", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:fPk4N6BV_jEC", "citedby": "1306"}, {"bib": {"title": "Genome remodelling in a basal-like breast cancer metastasis and xenograft", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cFHS6HbyZ2cC", "citedby": "1134"}, {"bib": {"title": "Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2tRrZ1ZAMYUC", "citedby": "1123"}, {"bib": {"title": "Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:pyW8ca7W8N0C", "citedby": "981"}, {"bib": {"title": "Whole-genome analysis informs breast cancer response to aromatase inhibition", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_xSYboBqXhAC", "citedby": "909"}, {"bib": {"title": "Prospective validation of a 21-gene expression assay in breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-95Q15plzcUC", "citedby": "876"}, {"bib": {"title": "Proteogenomic characterization of human colon and rectal cancer", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:37UQlXuwjP4C", "citedby": "801"}, {"bib": {"title": "Circulating tumor cells versus imaging\u2014predicting overall survival in metastatic breast cancer", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4X0JR2_MtJMC", "citedby": "797"}, {"bib": {"title": "Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yD5IFk8b50cC", "citedby": "789"}, {"bib": {"title": "Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on \u2026", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:D03iK_w7-QYC", "citedby": "739"}, {"bib": {"title": "Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:a0OBvERweLwC", "citedby": "734"}, {"bib": {"title": "Proteogenomics connects somatic mutations to signalling in breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BAanoTsO0WEC", "citedby": "688"}, {"bib": {"title": "HER2 and response to paclitaxel in node-positive breast cancer", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:f2IySw72cVMC", "citedby": "646"}, {"bib": {"title": "A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor\u2013positive breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NhqRSupF_l8C", "citedby": "633"}, {"bib": {"title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1sJd4Hv_s6UC", "citedby": "586"}, {"bib": {"title": "Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:E8ajGqO0XoUC", "citedby": "563"}, {"bib": {"title": "Outcome prediction for estrogen receptor\u2013positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:abG-DnoFyZgC", "citedby": "488"}, {"bib": {"title": "Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor\u2013rich stage 2 to 3 breast cancer \u2026", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:xtRiw3GOFMkC", "citedby": "452"}, {"bib": {"title": "Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dTyEYWd-f8wC", "citedby": "450"}, {"bib": {"title": "Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:l7t_Zn2s7bgC", "citedby": "435"}, {"bib": {"title": "Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:EUQCXRtRnyEC", "citedby": "417"}, {"bib": {"title": "Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor \u2026", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:F1b5ZUV5XREC", "citedby": "407"}, {"bib": {"title": "Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qxL8FJ1GzNcC", "citedby": "406"}, {"bib": {"title": "Integrated proteogenomic characterization of human high-grade serous ovarian cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WMtz-WDmgKQC", "citedby": "391"}, {"bib": {"title": "Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:P5F9QuxV20EC", "citedby": "319"}, {"bib": {"title": "CDK4/6 inhibition triggers anti-tumour immunity", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mVC4hKzE2FoC", "citedby": "318"}, {"bib": {"title": "Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-Analysis", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u-coK7KVo8oC", "citedby": "306"}, {"bib": {"title": "A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hvmnpdAuIbkC", "citedby": "295"}, {"bib": {"title": "SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PR6Y55bgFSsC", "citedby": "285"}, {"bib": {"title": "A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil\u00ae) in controlling hot flashes in breast cancer survivors", "year": "2000"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:c59VksA5Vz4C", "citedby": "285"}, {"bib": {"title": "Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:7VEv-pLvLSsC", "citedby": "274"}, {"bib": {"title": "PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:7PzlFSSx8tAC", "citedby": "271"}, {"bib": {"title": "Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2v_ZtQDX9iAC", "citedby": "262"}, {"bib": {"title": "Lower-dose vs high-dose oral estradiol therapy of hormone receptor\u2013positive, aromatase inhibitor\u2013resistant advanced breast cancer: a phase 2 randomized study", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nb7KW1ujOQ8C", "citedby": "259"}, {"bib": {"title": "Practical implications of gene-expression-based assays for breast oncologists", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u9iWguZQMMsC", "citedby": "252"}, {"bib": {"title": "A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:B3FOqHPlNUQC", "citedby": "233"}, {"bib": {"title": "Mechanisms of aromatase inhibitor resistance", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:k_IJM867U9cC", "citedby": "227"}, {"bib": {"title": "Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:CHSYGLWDkRkC", "citedby": "221"}, {"bib": {"title": "PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor\u2013positive breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:OU6Ihb5iCvQC", "citedby": "214"}, {"bib": {"title": "Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27\u2014a randomized controlled phase III trial", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vRqMK49ujn8C", "citedby": "209"}, {"bib": {"title": "Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5awf1xo2G04C", "citedby": "202"}, {"bib": {"title": "PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zdjWy_NXXwUC", "citedby": "200"}, {"bib": {"title": "Treatment of metastatic breast cancer", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QVtou7C4vgoC", "citedby": "198"}, {"bib": {"title": "Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KxtntwgDAa4C", "citedby": "192"}, {"bib": {"title": "Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:p2g8aNsByqUC", "citedby": "191"}, {"bib": {"title": "Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized \u2018FIRST\u2019study", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:q3oQSFYPqjQC", "citedby": "189"}, {"bib": {"title": "The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast \u2026", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dshw04ExmUIC", "citedby": "189"}, {"bib": {"title": "Patterns and functional implications of rare germline variants across 12 cancer types", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Og1tA8FjbJAC", "citedby": "183"}, {"bib": {"title": "Development and verification of the PAM50-based Prosigna breast cancer gene signature assay", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1lhNe0rCu4AC", "citedby": "182"}, {"bib": {"title": "Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tS2w5q8j5-wC", "citedby": "182"}, {"bib": {"title": "Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BzfGm06jWhQC", "citedby": "177"}, {"bib": {"title": "The genomic landscape of breast cancer as a therapeutic roadmap", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8AbLer7MMksC", "citedby": "176"}, {"bib": {"title": "Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:738O_yMBCRsC", "citedby": "176"}, {"bib": {"title": "Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:UxriW0iASnsC", "citedby": "166"}, {"bib": {"title": "Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eH23hyXCXa4C", "citedby": "154"}, {"bib": {"title": "Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC. CTG MA. 5 randomized trial", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:fQNAKQ3IYiAC", "citedby": "152"}, {"bib": {"title": "The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8dzOF9BpDQoC", "citedby": "150"}, {"bib": {"title": "Letrozole in the neoadjuvant setting: the P024 trial", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Tiz5es2fbqcC", "citedby": "148"}, {"bib": {"title": "Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as \u2026", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:olpn-zPbct0C", "citedby": "138"}, {"bib": {"title": "Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eJXPG6dFmWUC", "citedby": "137"}, {"bib": {"title": "A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally \u2026", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:sJsF-0ZLhtgC", "citedby": "136"}, {"bib": {"title": "Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4fKUyHm3Qg0C", "citedby": "132"}, {"bib": {"title": "Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uWQEDVKXjbEC", "citedby": "128"}, {"bib": {"title": "Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PELIpwtuRlgC", "citedby": "120"}, {"bib": {"title": "Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tOudhMTPpwUC", "citedby": "120"}, {"bib": {"title": "NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor\u2013positive breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oYLFIHfuHKwC", "citedby": "118"}, {"bib": {"title": "Molecular basis of triple negative breast cancer and implications for therapy", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5ugPr518TE4C", "citedby": "114"}, {"bib": {"title": "Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SP6oXDckpogC", "citedby": "114"}, {"bib": {"title": "Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nWoA1JPTheMC", "citedby": "113"}, {"bib": {"title": "Defining breast cancer intrinsic subtypes by quantitative receptor expression", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:d1gkVwhDpl0C", "citedby": "112"}, {"bib": {"title": "Activation of the transforming growth factor \u03b2 signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WbkHhVStYXYC", "citedby": "111"}, {"bib": {"title": "Insulin-like growth factors in human breast cancer", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KWzIFqRkAKkC", "citedby": "111"}, {"bib": {"title": "Insulin-like growth factor expression in breast cancer epithelium and stroma", "year": "1992"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JP7YXuLIOvAC", "citedby": "110"}, {"bib": {"title": "European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (GCSF) Guidelines Working Party: EORTC guidelines for the use of \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Tfl4UtY-dJUC", "citedby": "109"}, {"bib": {"title": "Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer", "year": "1994"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JWITY9-sCbMC", "citedby": "109"}, {"bib": {"title": "Clinical implementation of the intrinsic subtypes of breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5Ul4iDaHHb8C", "citedby": "108"}, {"bib": {"title": "Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry\u2013Based Assays", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:AZju0d2GQJ0C", "citedby": "106"}, {"bib": {"title": "Overcoming endocrine therapy resistance by signal transduction inhibition.", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:08ZZubdj9fEC", "citedby": "106"}, {"bib": {"title": "Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor\u2013positive breast cancer in postmenopausal women", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LPZeul_q3PIC", "citedby": "104"}, {"bib": {"title": "Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eflP2zaiRacC", "citedby": "100"}, {"bib": {"title": "Long noncoding RNA MALAT1 suppresses breast cancer metastasis", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yCjxvIMm6_oC", "citedby": "94"}, {"bib": {"title": "Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hQUaER0FWQ4C", "citedby": "93"}, {"bib": {"title": "A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hGdtkIFZdKAC", "citedby": "93"}, {"bib": {"title": "Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy\u2013resistant breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hC7cP41nSMkC", "citedby": "92"}, {"bib": {"title": "Predicting response and survival in chemotherapy-treated triple-negative breast cancer", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:otzGkya1bYkC", "citedby": "91"}, {"bib": {"title": "Predicting response and survival in chemotherapy-treated triple-negative breast cancer", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:0KyAp5RtaNEC", "citedby": "91"}, {"bib": {"title": "Predicting endocrine therapy responsiveness in breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:M3NEmzRMIkIC", "citedby": "91"}, {"bib": {"title": "First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:K3LRdlH-MEoC", "citedby": "91"}, {"bib": {"title": "Virtual reality intervention for older women with breast cancer", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Bg7qf7VwUHIC", "citedby": "90"}, {"bib": {"title": "Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dBIO0h50nwkC", "citedby": "89"}, {"bib": {"title": "PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TiIbgCYny7sC", "citedby": "85"}, {"bib": {"title": "PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:VL0QpB8kHFEC", "citedby": "85"}, {"bib": {"title": "Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.", "year": "1996"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:OzeSX8-yOCQC", "citedby": "82"}, {"bib": {"title": "Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:sSrBHYA8nusC", "citedby": "81"}, {"bib": {"title": "Patient-derived xenograft (PDX) models in basic and translational breast cancer research", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:d4tt_xEv1X8C", "citedby": "80"}, {"bib": {"title": "A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor\u2013positive metastatic breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qe6vwMD2xtsC", "citedby": "79"}, {"bib": {"title": "CPTAC Assay Portal: a repository of targeted proteomic assays", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:v_xunPV0uK0C", "citedby": "78"}, {"bib": {"title": "International Ki67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:E7VqQtBCVmcC", "citedby": "77"}, {"bib": {"title": "Targeted degradation of BET proteins in triple-negative breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Gpwnp1kGG20C", "citedby": "75"}, {"bib": {"title": "Recommendations for collection and handling of specimens from group breast cancer clinical trials", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nPT8s1NX_-sC", "citedby": "75"}, {"bib": {"title": "ESR1 gene amplification in breast cancer: a common phenomenon?", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XiSMed-E-HIC", "citedby": "75"}, {"bib": {"title": "An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eAlLMO4JVmQC", "citedby": "73"}, {"bib": {"title": "Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wbdj-CoPYUoC", "citedby": "71"}, {"bib": {"title": "Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI \u2026", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RGFaLdJalmkC", "citedby": "69"}, {"bib": {"title": "Proteogenomic integration reveals therapeutic targets in breast cancer xenografts", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:sJK75vZXtG0C", "citedby": "66"}, {"bib": {"title": "Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor\u2013Positive \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:6ZzL7HXColQC", "citedby": "66"}, {"bib": {"title": "Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LWqeokA2EBkC", "citedby": "65"}, {"bib": {"title": "Research issues affecting preoperative systemic therapy for operable breast cancer", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:VOx2b1Wkg3QC", "citedby": "65"}, {"bib": {"title": "Phase II trial of temsirolimus in patients with metastatic breast cancer", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LGlY6t8CeOMC", "citedby": "64"}, {"bib": {"title": "The Cancer Genome Atlas: clinical applications for breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:fEOibwPWpKIC", "citedby": "63"}, {"bib": {"title": "The Cancer Genome Atlas: clinical applications for breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IHkkN1K1AlAC", "citedby": "63"}, {"bib": {"title": "Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nVrZBo8bIpAC", "citedby": "62"}, {"bib": {"title": "Proteome profiling outperforms transcriptome profiling for coexpression based gene function prediction", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Vztgr1qGG8IC", "citedby": "61"}, {"bib": {"title": "Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer.", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:6Zm5LS9gQ5UC", "citedby": "59"}, {"bib": {"title": "A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_B80troHkn4C", "citedby": "58"}, {"bib": {"title": "Topoisomerase II\u03b1 amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:D_sINldO8mEC", "citedby": "56"}, {"bib": {"title": "Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RXiHnyRawswC", "citedby": "56"}, {"bib": {"title": "Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3x-KLxxGyuUC", "citedby": "55"}, {"bib": {"title": "A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor\u2013positive metastatic breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:m4fbC6XIj1kC", "citedby": "54"}, {"bib": {"title": "A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:z8nqeaKD1nsC", "citedby": "54"}, {"bib": {"title": "Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:t6usbXjVLHcC", "citedby": "54"}, {"bib": {"title": "A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_Ybze24A_UAC", "citedby": "53"}, {"bib": {"title": "A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YB4bud6kWLwC", "citedby": "53"}, {"bib": {"title": "Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RfUwGJFMQ-0C", "citedby": "52"}, {"bib": {"title": "Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H)(APT trial) for node-negative, HER2-positive breast cancer (BC)", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XiVPGOgt02cC", "citedby": "52"}, {"bib": {"title": "CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2 \u2026", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:V3AGJWp-ZtQC", "citedby": "51"}, {"bib": {"title": "HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:43bX7VzcjpAC", "citedby": "50"}, {"bib": {"title": "Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin\u00ae, in resistant solid tumor malignancies", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BmWJbWwHJAwC", "citedby": "50"}, {"bib": {"title": "Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kRWSkSYxWN8C", "citedby": "50"}, {"bib": {"title": "Integrated bottom-up and top-down proteomics of patient-derived breast tumor xenografts", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:s9ia6_kGH2AC", "citedby": "49"}, {"bib": {"title": "Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Zh0EY9V9P6UC", "citedby": "48"}, {"bib": {"title": "Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H)(APT trial) for node-negative, HER2-positive breast cancer (BC).", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:i91s68tWr-MC", "citedby": "47"}, {"bib": {"title": "Genetic polymorphism at Val 80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-_dYPAW6P2MC", "citedby": "47"}, {"bib": {"title": "High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Mojj43d5GZwC", "citedby": "47"}, {"bib": {"title": "Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole \u2026", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SdhP9T11ey4C", "citedby": "45"}, {"bib": {"title": "PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline-and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eI34FqJmdUoC", "citedby": "44"}, {"bib": {"title": "Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QKtdBID3u5MC", "citedby": "44"}, {"bib": {"title": "Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:N5tVd3kTz84C", "citedby": "44"}, {"bib": {"title": "Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1qzjygNMrQYC", "citedby": "44"}, {"bib": {"title": "Rate of Chemotherapy Related Amenorrhea (CRA) Associated with Adjuvant Adriamycin and Cytoxan (AC) and Adriamycin and Cytoxan Followed by Taxol (AC+ T) in Early Stage Breast \u2026", "year": "2000"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PVgj2kMGcgYC", "citedby": "43"}, {"bib": {"title": "A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qwy9JoKyICEC", "citedby": "42"}, {"bib": {"title": "US breast cancer mortality trends in young women according to race", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:CYCckWUYoCcC", "citedby": "41"}, {"bib": {"title": "Successful targeting of ErbB2 receptors\u2014is PTEN the key?", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bnK-pcrLprsC", "citedby": "41"}, {"bib": {"title": "Body mass index, diabetes, and triple-negative breast cancer prognosis", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BUYA1_V_uYcC", "citedby": "39"}, {"bib": {"title": "Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:evX43VCCuoAC", "citedby": "39"}, {"bib": {"title": "A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the'FIRST'study", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-vzq6BoH5oUC", "citedby": "39"}, {"bib": {"title": "Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2\u2013positive breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9tXw7Op4-u0C", "citedby": "38"}, {"bib": {"title": "A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BPS1z4jHU5cC", "citedby": "38"}, {"bib": {"title": "Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WA5NYHcadZ8C", "citedby": "38"}, {"bib": {"title": "Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate?", "year": "2000"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-uzm3Y7AvW0C", "citedby": "38"}, {"bib": {"title": "Body mass index, PAM50 subtype, and outcomes in node-positive breast cancer: CALGB 9741 (Alliance)", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NMxIlDl6LWMC", "citedby": "37"}, {"bib": {"title": "Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: overall survival from the phase II'first'study", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QsKbpXNoaWkC", "citedby": "37"}, {"bib": {"title": "RUNX1 prevents oestrogen-mediated AXIN1 suppression and \u03b2-catenin activation in ER-positive breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RMgMIBzvq-4C", "citedby": "35"}, {"bib": {"title": "Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TesyEGJKHF4C", "citedby": "34"}, {"bib": {"title": "Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kzcrU_BdoSEC", "citedby": "34"}, {"bib": {"title": "Neoadjuvant endocrine therapy for breast cancer: medical perspectives", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eMMeJKvmdy0C", "citedby": "34"}, {"bib": {"title": "TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wkm4DBaukwsC", "citedby": "33"}, {"bib": {"title": "Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bEWYMUwI8FkC", "citedby": "33"}, {"bib": {"title": "p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905)", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Fu2w8maKXqMC", "citedby": "33"}, {"bib": {"title": "Abstract S1-1: Final Analysis of NCIC CTG MA. 27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary \u2026", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HE397vMXCloC", "citedby": "33"}, {"bib": {"title": "The RII\u03b2 regulatory subunit of protein kinase A binds to cAMP response element: an alternative cAMP signaling pathway", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BJrgspguQaEC", "citedby": "32"}, {"bib": {"title": "Reproducibility of differential proteomic technologies in CPTAC fractionated xenografts", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:sJPMR1oEGYQC", "citedby": "31"}, {"bib": {"title": "Computed tomography of testicular tumours: distribution of abdominal lymphadenopathy", "year": "1986"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tkaPQYYpVKoC", "citedby": "31"}, {"bib": {"title": "Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea", "year": "2000"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Y5dfb0dijaUC", "citedby": "30"}, {"bib": {"title": "The prognostic effects of somatic mutations in ER-positive breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ufKn5pxu7C0C", "citedby": "29"}, {"bib": {"title": "New concepts in breast cancer genomics and genetics", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Ug5p-4gJ2f0C", "citedby": "29"}, {"bib": {"title": "New concepts in breast cancer genomics and genetics", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bCjgOgSFrM0C", "citedby": "29"}, {"bib": {"title": "Racial differences in outcomes of triple-negative breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:W5xh706n7nkC", "citedby": "29"}, {"bib": {"title": "Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA. 27 adjuvant breast cancer aromatase inhibitor trial", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kz9GbA2Ns4gC", "citedby": "28"}, {"bib": {"title": "A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ye4kPcJQO24C", "citedby": "28"}, {"bib": {"title": "Chemotherapy-related amenorrhea after adjuvant paclitaxel\u2013trastuzumab (APT trial)", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:e5wmG9Sq2KIC", "citedby": "27"}, {"bib": {"title": "Neoadjuvant endocrine therapy for breast cancer: more questions than answers", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eq2jaN3J8jMC", "citedby": "27"}, {"bib": {"title": "Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8gBurD7jEYQC", "citedby": "26"}, {"bib": {"title": "FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:q1zXlPLtbUIC", "citedby": "26"}, {"bib": {"title": "The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2\u2212 invasive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:7Hz3ACDFbsoC", "citedby": "26"}, {"bib": {"title": "Molecular profiling of triple negative breast cancer", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_Re3VWB3Y0AC", "citedby": "26"}, {"bib": {"title": "Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WqliGbK-hY8C", "citedby": "26"}, {"bib": {"title": "Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy\u2014results from the ACOSOG Z1041 (Alliance) trial", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ojlX30-wUrgC", "citedby": "25"}, {"bib": {"title": "Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:w2UhwfzvF0QC", "citedby": "25"}, {"bib": {"title": "Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:URolC5Kub84C", "citedby": "25"}, {"bib": {"title": "ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast \u2026", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ODE9OILHJdcC", "citedby": "25"}, {"bib": {"title": "Neoadjuvant endocrine therapy for locally advanced breast cancer", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JoZmwDi-zQgC", "citedby": "25"}, {"bib": {"title": "Estrogen receptor expression and sensitivity to paclitaxel in breast cancer", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BOlwja0KXvYC", "citedby": "25"}, {"bib": {"title": "A Randomized Double-blind Multicenter Study of Pre-operative Tamoxifen Versus Femara\u2122(letrozole) for Postmenopausal Women with Er and/or Pgr Postive Breast Cancer Ineligible \u2026", "year": "2000"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1yQoGdGgb4wC", "citedby": "24"}, {"bib": {"title": "Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HqhvjgTjE9cC", "citedby": "23"}, {"bib": {"title": "The Z-cad dual fluorescent sensor detects dynamic changes between the epithelial and mesenchymal cellular states", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uUvzmPk0f8oC", "citedby": "23"}, {"bib": {"title": "Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:7T2F9Uy0os0C", "citedby": "23"}, {"bib": {"title": "Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Nnq8S6OXqDYC", "citedby": "22"}, {"bib": {"title": "Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB \u2026", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LgRImbQfgY4C", "citedby": "22"}, {"bib": {"title": "Prioritizing potentially druggable mutations with dGene: an annotation tool for cancer genome sequencing data", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:AvfA0Oy_GE0C", "citedby": "22"}, {"bib": {"title": "Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hkOj_22Ku90C", "citedby": "22"}, {"bib": {"title": "Neoadjuvant endocrine therapy as a drug development strategy", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZuybSZzF8UAC", "citedby": "22"}, {"bib": {"title": "EGF10004: a randomized, multicenter, phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mNrWkgRL2YcC", "citedby": "22"}, {"bib": {"title": "Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2Q0AJrNhS-QC", "citedby": "21"}, {"bib": {"title": "Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4aZ_i-5WJEQC", "citedby": "20"}, {"bib": {"title": "Methods and Compositions Involving Intrinsic Genes", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KlAtU1dfN6UC", "citedby": "20"}, {"bib": {"title": "Mass Spectrometry\u2013Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nOiSByfp82kC", "citedby": "19"}, {"bib": {"title": "Breast cancer neoantigens can induce CD8+ T-cell responses and antitumor immunity", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Gb6Hms-Uo9kC", "citedby": "19"}, {"bib": {"title": "Using the CPTAC Assay Portal to identify and implement highly characterized targeted proteomics assays", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tz746QTLzJkC", "citedby": "19"}, {"bib": {"title": "Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TlpoogIpr_IC", "citedby": "19"}, {"bib": {"title": "ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC-> P+ T) with paclitaxel plus trastuzumab \u2026", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JQOojiI6XY0C", "citedby": "19"}, {"bib": {"title": "Proteomic profiling identifies key coactivators utilized by mutant ER\u03b1 proteins as potential new therapeutic targets", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hEXC_dOfxuUC", "citedby": "18"}, {"bib": {"title": "Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GJVTs2krol4C", "citedby": "18"}, {"bib": {"title": "Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:adHtZc2wMuEC", "citedby": "18"}, {"bib": {"title": "Incorporating genomics into breast cancer clinical trials and care", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nrtMV_XWKgEC", "citedby": "18"}, {"bib": {"title": "Abstract PD07-01: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy Based on 2 to 4 week Ki67 level> 10%.", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HtS1dXgVpQUC", "citedby": "17"}, {"bib": {"title": "Incidence of 25-OH vitamin D deficiency in patients with a history of breast cancer who have musculoskeletal symptomatology", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uLbwQdceFCQC", "citedby": "17"}, {"bib": {"title": "Trawling for genes that predict response to breast cancer adjuvant therapy", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oPLKW5k6eA4C", "citedby": "16"}, {"bib": {"title": "A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dQ2og3OwTAUC", "citedby": "16"}, {"bib": {"title": "Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DGzKIA18-3YC", "citedby": "15"}, {"bib": {"title": "Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:B2rIPIGFPLEC", "citedby": "15"}, {"bib": {"title": "Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:C-Rn0OCouf8C", "citedby": "15"}, {"bib": {"title": "Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC)", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yMeIxYmEMEAC", "citedby": "15"}, {"bib": {"title": "Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oldoQiaHq2UC", "citedby": "14"}, {"bib": {"title": "Molecular pathways: extracting medical knowledge from high-throughput genomic data", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zLWjf1WUPmwC", "citedby": "14"}, {"bib": {"title": "Cancer genome sequencing and its implications for personalized cancer vaccines", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LK8CI43ZvvMC", "citedby": "14"}, {"bib": {"title": "Response: Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2P1L_qKh6hAC", "citedby": "14"}, {"bib": {"title": "Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NJ774b8OgUMC", "citedby": "14"}, {"bib": {"title": "Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oTdOBqtIf_kC", "citedby": "13"}, {"bib": {"title": "A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:UHK10RUVsp4C", "citedby": "13"}, {"bib": {"title": "DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RJNGbXJAtMsC", "citedby": "12"}, {"bib": {"title": "Reactivation of p53 by MDM2 inhibitor MI-77301 for the treatment of endocrine-resistant breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qCpRzq7zkD8C", "citedby": "12"}, {"bib": {"title": "Abstract PD1-4: A phase I study of BKM120 and fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:pYKElYtJMmwC", "citedby": "12"}, {"bib": {"title": "Abstract PD1-4: A phase I study of BKM120 and fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wE-fMHVdjMkC", "citedby": "12"}, {"bib": {"title": "Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:sA9dB-pw3HoC", "citedby": "12"}, {"bib": {"title": "Mutational analysis of breast cancer: guiding personalized treatments", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LI9QrySNdTsC", "citedby": "12"}, {"bib": {"title": "Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2KloaMYe4IUC", "citedby": "12"}, {"bib": {"title": "ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u_mOZUIutIEC", "citedby": "11"}, {"bib": {"title": "The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:MDX3w3dAD3YC", "citedby": "11"}, {"bib": {"title": "A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tzM49s52ZIMC", "citedby": "11"}, {"bib": {"title": "ICI 182,780 (Faslodex\u2122) versus anastrozole (Arimidex\u2122) for the treatment of advanced breast cancer in postmenopausal women\u2014prospective combined analysis of two multicenter \u2026", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tKAzc9rXhukC", "citedby": "11"}, {"bib": {"title": "gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TeJ9juy8vcMC", "citedby": "10"}, {"bib": {"title": "Using the 6-minute walk test to predict disability-free survival after major surgery", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:o9ULDYDKYbIC", "citedby": "10"}, {"bib": {"title": "Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5rMqqAh47xYC", "citedby": "10"}, {"bib": {"title": "Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:j8pvxH-kN2QC", "citedby": "10"}, {"bib": {"title": "ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:e_rmSamDkqQC", "citedby": "10"}, {"bib": {"title": "Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:z_wVstp3MssC", "citedby": "10"}, {"bib": {"title": "Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:OTTXONDVkokC", "citedby": "10"}, {"bib": {"title": "Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:i2xiXl-TujoC", "citedby": "10"}, {"bib": {"title": "A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil [R]) in controlling hot flashes", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:t-hv7AR41mYC", "citedby": "10"}, {"bib": {"title": "Reversal of hepatic encephalopathy and alteration in amino acid profiles after blocking a surgical splenorenal shunt by interventional radiological techniques", "year": "1989"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JH5k92_tO-AC", "citedby": "10"}, {"bib": {"title": "ESR1 alterations and metastasis in estrogen receptor positive breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QeguYG95ZbAC", "citedby": "9"}, {"bib": {"title": "Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance \u2026", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IyxfXMz2bNAC", "citedby": "9"}, {"bib": {"title": "Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:J3LtWjKFLicC", "citedby": "9"}, {"bib": {"title": "Methods of treating breast cancer with anthracycline therapy", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:j2GSQqY3pL0C", "citedby": "9"}, {"bib": {"title": "Methods of treating breast cancer with anthracycline therapy", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:FAceZFleit8C", "citedby": "9"}, {"bib": {"title": "Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA. 27 adjuvant aromatase inhibitor trial.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:35r97b3x0nAC", "citedby": "9"}, {"bib": {"title": "Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ILKRHgRFtOwC", "citedby": "9"}, {"bib": {"title": "A supervised risk predictor of breast cancer based on biological subtypes", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:t7zJ5fGR-2UC", "citedby": "9"}, {"bib": {"title": "A luminal breast cancer genome atlas: progress and barriers", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9Nmd_mFXekcC", "citedby": "9"}, {"bib": {"title": "Role of biologic markers in patient selection and application to disease prevention.", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uWiczbcajpAC", "citedby": "9"}, {"bib": {"title": "Letrozole in the treatment of breast cancer", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:VLnqNzywnoUC", "citedby": "9"}, {"bib": {"title": "NF-\u03f0B-independent activation of \u03b2-interferon expression in mouse F9 embryonal carcinoma cells", "year": "1994"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XtJa11BXPS4C", "citedby": "9"}, {"bib": {"title": "Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the \u2026", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mgoTDWlsYNUC", "citedby": "8"}, {"bib": {"title": "Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8p8iYwVyaVcC", "citedby": "8"}, {"bib": {"title": "Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor\u2013positive breast cancer: NCIC CTG MA. 27", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kO05sadLmrgC", "citedby": "8"}, {"bib": {"title": "Methods of treating breast cancer with taxane therapy", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WM2K3OHRCGMC", "citedby": "8"}, {"bib": {"title": "Methods of treating breast cancer with taxane therapy", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4JMBOYKVnBMC", "citedby": "8"}, {"bib": {"title": "Development of rational drug combinations with investigational targeted agents", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Z5m8FVwuT1cC", "citedby": "8"}, {"bib": {"title": "Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uc_IGeMz5qoC", "citedby": "8"}, {"bib": {"title": "Endocrine therapy for breast cancer", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:EkHepimYqZsC", "citedby": "8"}, {"bib": {"title": "Breast Cancer Gene Expression Analysis", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uJ-U7cs_P_0C", "citedby": "8"}, {"bib": {"title": "Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SgM-ki2adj0C", "citedby": "7"}, {"bib": {"title": "FGFR1-activated translation of WNT pathway components with structured 5\u2032 UTRs is vulnerable to inhibition of EIF4A-dependent translation initiation", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_IsBomjs8bsC", "citedby": "7"}, {"bib": {"title": "ACOSOG Z1041 (Alliance): Cardiac events (CE) among those receiving neoadjuvant anthracyclines (A) and taxanes with trastuzumab (T) for HER2+ breast cancer.", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-FonjvnnhkoC", "citedby": "7"}, {"bib": {"title": "The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC. CTG MA. 5 randomized trial.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:EYYDruWGBe4C", "citedby": "7"}, {"bib": {"title": "Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA. 27 Adjuvant Aromatase Inhibitor Trial.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:j8SEvjWlNXcC", "citedby": "7"}, {"bib": {"title": "Improving Outcomes for Patients With Hormone Receptor\u2013Positive Breast Cancer: Back to the Drawing Board", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yB1At4FlUx8C", "citedby": "7"}, {"bib": {"title": "Outcome prediction for clinical stage II and III ER+ breast cancer based on treatment response, pathological stage, tumor grade, Ki67 proliferation index, and estrogen receptor \u2026", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZfRJV9d4-WMC", "citedby": "7"}, {"bib": {"title": "Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:aIdbFUkbNIkC", "citedby": "7"}, {"bib": {"title": "Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA. 12 Trial and BC Cohort", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:0N-VGjzr574C", "citedby": "6"}, {"bib": {"title": "PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bz8QjSJIRt4C", "citedby": "6"}, {"bib": {"title": "The natural history of hormone receptor\u2013positive breast cancer: attempting to decipher an intriguing concept", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:v6i8RKmR8ToC", "citedby": "6"}, {"bib": {"title": "The other triple-negative breast cancer: Immunohistochemical and clinicopathologic characterization of the Claudin-low subtype.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:MLfJN-KU85MC", "citedby": "6"}, {"bib": {"title": "Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:p__nRnzSRKYC", "citedby": "6"}, {"bib": {"title": "I'm pregnant and I have breast cancer", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hMsQuOkrut0C", "citedby": "6"}, {"bib": {"title": "Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:M7yex6snE4oC", "citedby": "6"}, {"bib": {"title": "Neoadjuvant endocrine therapy for breast cancer: an overlooked option?", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XD-gHx7UXLsC", "citedby": "6"}, {"bib": {"title": "Letrozole (Femara\u00ae) is a more effective anti-proliferative agent than tamoxifen irrespective of ErbB1 and/or ErbB2 positive status: evidence from a phase III randomized trial \u2026", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ipzZ9siozwsC", "citedby": "6"}, {"bib": {"title": "The insulin-like growth factor network and breast cancer", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:lYAcb2jw7qUC", "citedby": "6"}, {"bib": {"title": "Mortality in patients with testicular cancer: report of the Anglia and Trent testicular tumour groups.", "year": "1986"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vbGhcppDl1QC", "citedby": "6"}, {"bib": {"title": "Value of follow up in testicular cancer.", "year": "1984"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SpbeaW3--B0C", "citedby": "6"}, {"bib": {"title": "Cancer incidence and mortality rates and trends in Trinidad and Tobago", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5VjbC5aozO0C", "citedby": "5"}, {"bib": {"title": "Avoidance of negative results in adjuvant endocrine therapy trials for estrogen receptor\u2013positive breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:AFXcoJnoRH0C", "citedby": "5"}, {"bib": {"title": "Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rO6llkc54NcC", "citedby": "5"}, {"bib": {"title": "HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_FM0Bhl9EiAC", "citedby": "5"}, {"bib": {"title": "A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor \u2026", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SIv7DqKytYAC", "citedby": "5"}, {"bib": {"title": "Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:60iIaj97TE0C", "citedby": "5"}, {"bib": {"title": "Abstract S1-3: A Comparison of Fulvestrant 500 mg with Anastrozole as First-Line Treatment for Advanced Breast Cancer: Follow-Up Analysis from the \u2018FIRST\u2019Study", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:J-pR_7NvFogC", "citedby": "5"}, {"bib": {"title": "Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel \u2026", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5icHVeHT4IsC", "citedby": "5"}, {"bib": {"title": "A Double-Blind, Randomized, Placebo-Controlled Trial of High Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast Cancer \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:S16KYo8Pm5AC", "citedby": "5"}, {"bib": {"title": "Lower-dose (6 mg Daily) versus High-dose (30 mg Daily) Oral Estradiol Therapy of Hormone-receptor-positive, Aromatase-inhibitor-resistant Advanced Breast Cancer: A Randomized \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:foquWX3nUaYC", "citedby": "5"}, {"bib": {"title": "A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jmjb1lOE9QIC", "citedby": "5"}, {"bib": {"title": "Expression of estrogen responsive genes in breast cancers correlates with plasma estradiol levels in postmenopausal women.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KUbvn5osdkgC", "citedby": "5"}, {"bib": {"title": "A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QYdC8u9Cj1oC", "citedby": "5"}, {"bib": {"title": "\u201cPIKing\u201d the Winner for Phosphatidylinositol 3-Kinase Inhibitors in ErbB2-Positive Breast Cancer: Let's Not \u201cPTENed\u201d It's Easy!", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:VaXvl8Fpj5cC", "citedby": "5"}, {"bib": {"title": "Femara\u00ae and the future: tailoring treatment and combination therapies with Femara", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4MWp96NkSFoC", "citedby": "5"}, {"bib": {"title": "Circulating tumor cells-not serum tumor markers-predict survival in metastatic breast cancer", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IRz6iEL74y4C", "citedby": "5"}, {"bib": {"title": "Circulating tumor cells are a reliable predictor of progression free survival and overall survival during therapy of patients with metastatic breast cancer", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yFnVuubrUp4C", "citedby": "5"}, {"bib": {"title": "Refining breast cancer risk assessment with molecular markers: the next step?", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vDijr-p_gm4C", "citedby": "5"}, {"bib": {"title": "Improving hormonal therapy for breast cancer", "year": "1997"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_AeoHAGD03cC", "citedby": "5"}, {"bib": {"title": "Local\u2013regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jq04SsiGh3QC", "citedby": "4"}, {"bib": {"title": "Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:gFrPXmx1TSsC", "citedby": "4"}, {"bib": {"title": "DNA damage repair defects as a new class of endocrine treatment resistance driver", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:w7CBUyPWg-0C", "citedby": "4"}, {"bib": {"title": "Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor\u2013Treated Patients: CCTG MA. 27", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HKviVsUxM5wC", "citedby": "4"}, {"bib": {"title": "Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:htyGaKyDgHMC", "citedby": "4"}, {"bib": {"title": "An mRNA Gene Expression\u2013Based Signature to Identify FGFR1-Amplified Estrogen Receptor\u2013Positive Breast Tumors", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hfzGNhXhx5MC", "citedby": "4"}, {"bib": {"title": "QuantFusion: novel unified methodology for enhanced coverage and precision in quantifying global proteomic changes in whole tissues", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SxCCDk4iOpsC", "citedby": "4"}, {"bib": {"title": "Abstract S1-02: Prognostic effects of gene mutation in estrogen receptor positive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ufrVoPGSRksC", "citedby": "4"}, {"bib": {"title": "Methods And Compositions Involving Intrinsic Genes", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4DMP91E08xMC", "citedby": "4"}, {"bib": {"title": "Abstract P2-13-02: Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG \u2026", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HbR8gkJAVGIC", "citedby": "4"}, {"bib": {"title": "Abstract S1-2: ACOSOG Z1031: A Randomized Neoadjuvant Comparison between Letrozole (LET), Anastrozole (ANA) and Exemestane (EXE) for Postmenopausal Women with ER Rich Stage 2/3 \u2026", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZzlSgRqYykMC", "citedby": "4"}, {"bib": {"title": "Neoadjuvant endocrine therapy for breast cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tuHXwOkdijsC", "citedby": "4"}, {"bib": {"title": "Mechanisms of action of selective estrogen receptor modulators", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:b1wdh0AR-JQC", "citedby": "4"}, {"bib": {"title": "Breast cancer molecular subtypes and locoregional recurrence", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:epqYDVWIO7EC", "citedby": "4"}, {"bib": {"title": "Cell-cycle complete response after neoadjuvant letrozole predicts superior relapse-free and overall survival: long-term follow-up of the letrozole P024 study", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:L7CI7m0gUJcC", "citedby": "4"}, {"bib": {"title": "High nuclear p27kip1 levels predicts sensitivity to neoadjuvant letrozole in ER+ breast cancer independent of pAKT levels, PIK3CA mutation status and cell cycle effects: a \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WZBGuue-350C", "citedby": "4"}, {"bib": {"title": "Circulating epithelial cells in breast cancer.", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4Yq6kJLCcecC", "citedby": "4"}, {"bib": {"title": "Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Oo1CbQkBAzEC", "citedby": "4"}, {"bib": {"title": "Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nZcligLrVowC", "citedby": "4"}, {"bib": {"title": "Correlation of changes in circulating tumor cells and radiographic response to treatment in patients with metastatic breast cancer", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:lvd772isFD0C", "citedby": "4"}, {"bib": {"title": "Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZYsTHYU9jrMC", "citedby": "3"}, {"bib": {"title": "ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vofGIMt6cyEC", "citedby": "3"}, {"bib": {"title": "Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:J4E9jCG1tHUC", "citedby": "3"}, {"bib": {"title": "Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER+ Breast Cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bVQMTfhMCi4C", "citedby": "3"}, {"bib": {"title": "A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:inmFHauC9wsC", "citedby": "3"}, {"bib": {"title": "Methods of treating breast cancer with anthracycline therapy", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ehoypfNsBj8C", "citedby": "3"}, {"bib": {"title": "Abstract P4-11-13: Validation of the preoperative endocrine prognostic index in the ACOSOG (Alliance) Z1031 neoadjuvant aromatase inhibitor trial", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:UeHWp8X0CEIC", "citedby": "3"}, {"bib": {"title": "Abstract LB-87: Analysis of luminal-type breast cancer by massively parallel sequencing", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TQgYirikUcIC", "citedby": "3"}, {"bib": {"title": "Taxane-Based Chemotherapy for Node-Positive Breast Cancer\u2014Take-Home Lessons", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:k8Z6L05lTy4C", "citedby": "3"}, {"bib": {"title": "Current and future choices in endocrine therapy", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:gsN89kCJA0AC", "citedby": "3"}, {"bib": {"title": "S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:G1UMdFYMoxkC", "citedby": "3"}, {"bib": {"title": "Absence of post treatment tumour expression of aromatase is associated with reduced antiproliferative effects of letrozole (but not tamoxifen) in the P024 adjuvant endocrine \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:lmc2jWPfTJgC", "citedby": "3"}, {"bib": {"title": "Functional analysis of the breast cancer genome", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Dip1O2bNi0gC", "citedby": "3"}, {"bib": {"title": "Circulating tumor cells-not serum tumor markers-predict survival in metastatic breast cancer", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:F9fV5C73w3QC", "citedby": "3"}, {"bib": {"title": "The role of HER-2+ Topo II\u03b1 amplification in predicting benefit from CAF dose escalation-CALGB 8541", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:feST4K8J0scC", "citedby": "3"}, {"bib": {"title": "The role of HER-2+ Topo II\u03b1 amplification in predicting benefit from CAF dose escalation-CALGB 8541", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:g3aElNc5_aQC", "citedby": "3"}, {"bib": {"title": "Changes in tumor grade with neoadjuvant endocrine therapy: morphological evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TIZ-Mc8IlK0C", "citedby": "3"}, {"bib": {"title": "Letrozole (Femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for \u2026", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tYavs44e6CUC", "citedby": "3"}, {"bib": {"title": "Proteogenomic Characterization of Endometrial Carcinoma", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PklR0melJeUC", "citedby": "2"}, {"bib": {"title": "Microscaled proteogenomic methods for precision oncology", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Mx5hWS9ctUkC", "citedby": "2"}, {"bib": {"title": "A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qCaWouos7ogC", "citedby": "2"}, {"bib": {"title": "MiRNAs and long-term breast cancer survival: Evidence from the WHEL Study", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:onKP9CxGSkIC", "citedby": "2"}, {"bib": {"title": "Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:L7vk9XBBNxgC", "citedby": "2"}, {"bib": {"title": "Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone \u2026", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Cvh0bltMcLgC", "citedby": "2"}, {"bib": {"title": "Fulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral vs non-visceral metastases: findings from FALCON, FIRST, and CONFIRM", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rpSJNIKeXWsC", "citedby": "2"}, {"bib": {"title": "Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2 (mut)) screening and response monitoring to neratinib in metastatic breast cancer (MBC)", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IvSMUa3B7yYC", "citedby": "2"}, {"bib": {"title": "Health-related quality of life from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON).", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4QKQTXcH0q8C", "citedby": "2"}, {"bib": {"title": "Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Nufq_to8ts0C", "citedby": "2"}, {"bib": {"title": "Gene expression profiles to predict breast cancer outcomes", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:xyvS_IvSCKsC", "citedby": "2"}, {"bib": {"title": "A co-clinical phase II trial of carboplatin and docetaxel as neoadjuvant treatment for triple negative breast cancer with genomic discovery analysis.", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NtGNdKbuCngC", "citedby": "2"}, {"bib": {"title": "A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:lRPiJ3GhvscC", "citedby": "2"}, {"bib": {"title": "36: Proffered Paper: Proteogenomic analysis of human breast cancer connects genetic alterations to phosphorylation networks", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5nxA0vEk-isC", "citedby": "2"}, {"bib": {"title": "Genomic analysis of breast cancer heralds a changing treatment paradigm", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YohjEiUPhakC", "citedby": "2"}, {"bib": {"title": "Abstract P6-07-10: Luminal A vs. Basal-like Breast Cancer: time dependent changes in the risk of relapse in the absence of treatment", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ruyezt5ZtCIC", "citedby": "2"}, {"bib": {"title": "A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer.", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9pM33mqn1YgC", "citedby": "2"}, {"bib": {"title": "Whole genome sequencing to characterize luminal-type breast cancer.", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PoWvk5oyLR8C", "citedby": "2"}, {"bib": {"title": "Neoadjuvant aromatase inhibitor therapy permits breast conservation in postmenopausal women with large, estrogen receptor (ER)-rich breast cancer facing mastectomy: results \u2026", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HIFyuExEbWQC", "citedby": "2"}, {"bib": {"title": "Research training in breast cancer for low and middle income countries", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TaaCk18tZOkC", "citedby": "2"}, {"bib": {"title": "Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results \u2026", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kuK5TVdYjLIC", "citedby": "2"}, {"bib": {"title": "[Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer].", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ClCfbGk0d_YC", "citedby": "2"}, {"bib": {"title": "Tumour aromatase as measured by immunohistochemistry in patients treated neoadjuvantly with either letrozole or tamoxifen in the P024 randomised trial\u2014correlations with other \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:q3CdL3IzO_QC", "citedby": "2"}, {"bib": {"title": "Prognostic and predictive value of circulating tumor cells in metastatic breast cancer patients treated with endocrine or chemotherapy", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_5tno0g5mFcC", "citedby": "2"}, {"bib": {"title": "Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GtLg2Ama23sC", "citedby": "2"}, {"bib": {"title": "Estrogen-independent cell proliferation occurs in the majority of estrogen receptor positive (ER+)/HER2 gene-amplified primary breast cancers: evidence from a combined analysis \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BwyfMAYsbu0C", "citedby": "2"}, {"bib": {"title": "A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:U5uP8zs9lfgC", "citedby": "2"}, {"bib": {"title": "A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:xtoqd-5pKcoC", "citedby": "2"}, {"bib": {"title": "based PAM50 signature and long-term breast cancer survival", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8JTMrWI6FdcC", "citedby": "1"}, {"bib": {"title": "Copy number alterations associated with clinical features in an underrepresented population with breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RgznTc0nqo4C", "citedby": "1"}, {"bib": {"title": "A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qbqt7gslDFUC", "citedby": "1"}, {"bib": {"title": "Endocrine Therapy in Clinical Practice", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:j7XjBeKFbTsC", "citedby": "1"}, {"bib": {"title": "Fulvestrant in management of hormone receptor-positive metastatic breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:e3CVSTJ63dQC", "citedby": "1"}, {"bib": {"title": "Abstract GS2-02: Direct regulation of estrogen receptor-\u03b1 (ER) transcriptional activity by NF1", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cdwqcPQS8ssC", "citedby": "1"}, {"bib": {"title": "Abstract P4-04-01: Loss of mismatch repair predicts resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors in ER+ breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZysSsiWj_g4C", "citedby": "1"}, {"bib": {"title": "Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_9Xh93LWpsYC", "citedby": "1"}, {"bib": {"title": "Current Challenges Associated With Next-Generation Sequencing of Breast Cancer\u2014Reply", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:M0j1y4EgrScC", "citedby": "1"}, {"bib": {"title": "Discovery and characterization of late-stage breast cancer estrogen receptor alpha 1 bound long non-coding RNAs", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GiYFt9mpioMC", "citedby": "1"}, {"bib": {"title": "Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:CRzUtm-VnGAC", "citedby": "1"}, {"bib": {"title": "Abstract P2-08-09: Progression-free survival results in postmenopausal Asian women: Subgroup analysis from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cSdaV2aYdYsC", "citedby": "1"}, {"bib": {"title": "Abstract PD1-04: CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9LpHyFPp1DQC", "citedby": "1"}, {"bib": {"title": "Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vjZqxyZ7hS4C", "citedby": "1"}, {"bib": {"title": "Maximal exercise does not increase ventilation heterogeneity in healthy trained adults", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:aEW5N-EHWIMC", "citedby": "1"}, {"bib": {"title": "A phase II neoadjuvant trial of MK-2206, an AKT inhibitor, in combination with anastrozole for clinical stage 2 or 3 PIK3CA mutant estrogen receptor positive HER2 negative (ER+ \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_mQi-xiA4oYC", "citedby": "1"}, {"bib": {"title": "Abstract IA29: Proteogenomic and phosphoproteomic analysis of breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cBPnxVikjH8C", "citedby": "1"}, {"bib": {"title": "Methods of treating breast cancer with taxane therapy", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KqnX2w3egDsC", "citedby": "1"}, {"bib": {"title": "Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:iH-uZ7U-co4C", "citedby": "1"}, {"bib": {"title": "A copy number aberration driven endocrine response gene signature stratifies risk in estrogen receptor positive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:37Fl7vPTsUIC", "citedby": "1"}, {"bib": {"title": "CADER prognostic gene signature for disease free survival in hormone receptor positive breast cancer: NCIC CTG MA. 12 phase III placebo-controlled tamoxifen trial", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jL-93Qbq4QoC", "citedby": "1"}, {"bib": {"title": "Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II \u2018FIRST\u2019study", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GnPB-g6toBAC", "citedby": "1"}, {"bib": {"title": "Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Wp0gIr-vW9MC", "citedby": "1"}, {"bib": {"title": "Patient-derived xenograft study reveals the pharmacology and the role of ESR1 gene aberrations in endocrine therapy resistance of ER positive breast cancer", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:W7OEmFMy1HYC", "citedby": "1"}, {"bib": {"title": "Proteogenomic Analysis of Human Breast Cancer Connects Genetic Alterations to Phosphorylation Networks", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:35N4QoGY0k4C", "citedby": "1"}, {"bib": {"title": "A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jtI9f0ekYq0C", "citedby": "1"}, {"bib": {"title": "The development of a standardized Ki-67 assay for the ALTERNATE trial: an experience in academic investigational device development", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:I8rxH6phXEkC", "citedby": "1"}, {"bib": {"title": "Abstract S3-05: Patient-derived xenograft study reveals endocrine therapy resistance of ER+ breast cancer caused by distinct ESR1 gene aberrations", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rmuvC79q63oC", "citedby": "1"}, {"bib": {"title": "Abstract OT3-2-09: FALCON: A randomised, double-blind, multicentre, phase III study comparing fulvestrant 500 mg with anastrozole 1 mg for postmenopausal women with hormone \u2026", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4TOpqqG69KYC", "citedby": "1"}, {"bib": {"title": "Abstract P3-05-10: The development of a standardized Ki-67 assay for the ALTERNATE trial: An experience in academic investigational device development", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hqOjcs7Dif8C", "citedby": "1"}, {"bib": {"title": "Abstract S5-6: Activating HER2 mutations in HER2 gene amplification negative breast cancers.", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oNZyr7d5Mn4C", "citedby": "1"}, {"bib": {"title": "Optimizing treatment in luminal breast cancer", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HtEfBTGE9r8C", "citedby": "1"}, {"bib": {"title": "Clinical and correlative science results in a phase II study of UCN-01 in combination with irinotecan in recurrent triple-negative breast cancer (TNBC).", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wLxue7F8ec0C", "citedby": "1"}, {"bib": {"title": "P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hCrLmN-GePgC", "citedby": "1"}, {"bib": {"title": "P1-06-13: An Amplicon-Driven Aromatase Inhibitor Response (ADAIR) Signature Provides an Orthogonal Risk Classifier for ER+ Breast Cancer.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hMod-77fHWUC", "citedby": "1"}, {"bib": {"title": "P153 Measuring variation in decision making within lung cancer multidisciplinary team (MDT) meetings\u2013a pilot study", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Hck25ST_3aIC", "citedby": "1"}, {"bib": {"title": "PARP inhibitors and their evolving role in breast cancer", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YTuZlYwrTOUC", "citedby": "1"}, {"bib": {"title": "Management of premenopausal women with neoadjuvant endocrine therapy: A single institution experience.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:UmS_249rOGwC", "citedby": "1"}, {"bib": {"title": "Understanding the Estrogen Receptor\u2013Positive Breast Cancer Genome: Not Even the End of the Beginning", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:r0BpntZqJG4C", "citedby": "1"}, {"bib": {"title": "Measuring the impact of Z1031 on clinical practice", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Ri6SYOTghG4C", "citedby": "1"}, {"bib": {"title": "Amplification of the FGRF1 Gene and Its Relationship with Gene Expression and Clinical Significance in Breast Cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:OcBU2YAGkTUC", "citedby": "1"}, {"bib": {"title": "Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mlAyqtXpCwEC", "citedby": "1"}, {"bib": {"title": "A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kh2fBNsKQNwC", "citedby": "1"}, {"bib": {"title": "The Effect of the IGF1R Antibody R1507 on ER Positive Breast Cancer Cell Lines Growth and Survival.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kNdYIx-mwKoC", "citedby": "1"}, {"bib": {"title": "Targeted therapies for triple negative breast cancer based on TP53 status.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:artPoR2Yc-kC", "citedby": "1"}, {"bib": {"title": "A comparison of high-dose (HD, 500 mg) fulvestrant vs anastrozole (1 mg) as first-line treatments for advanced breast cancer: results from FIRST.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PVjk1bu6vJQC", "citedby": "1"}, {"bib": {"title": "Phosphatidyl-inositol-3-kinase Alpha catalytic subunit kinase domain mutations impart a favorable prognosis on estrogen receptor positive breast cancer through a mechanism that \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:edDO8Oi4QzsC", "citedby": "1"}, {"bib": {"title": "A phase 2 trial of neoadjuvant letrozole for postmenopausal patients with stage 2 and 3 ER and/or PgR+ breast cancer-endpoint comparisons", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5qfkUJPXOUwC", "citedby": "1"}, {"bib": {"title": "Ki-67 is a Luminal B marker that identifies a high-risk subgroup in hormone receptor positive and node negative breast cancer", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3fE2CSJIrl8C", "citedby": "1"}, {"bib": {"title": "The challenges and pitfalls of delivering breast cancer multigene diagnostic assays to the clinic", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:FPJr55Dyh1AC", "citedby": "1"}, {"bib": {"title": "Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: results from a pilot study in CALGB 9342", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XoXfffV-tXoC", "citedby": "1"}, {"bib": {"title": "Circulating epithelial cells in breast cancer", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TGkaJS32XoUC", "citedby": "1"}, {"bib": {"title": "Detection of circulating tumor cells (CTCs) is a prognostic factor in first-line metastatic breast cancer (MBC)", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BJbdYPG6LGMC", "citedby": "1"}, {"bib": {"title": "A comparison study of 18F-labeled choline versus 18F-labeled 2-deoxyglucose positron emission tomography for evaluation of advanced breast cancer.", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Oj-SLI0tZTcC", "citedby": "1"}, {"bib": {"title": "Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Summary Consensus Statement", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u0Mu_IsstPMC", "citedby": "1"}, {"bib": {"title": "Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Summary Consensus Statement", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_axFR9aDTf0C", "citedby": "1"}, {"bib": {"title": "Metastatic bone disease and the role of bisphosphonates.", "year": "1996"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yqoGN6RLRZoC", "citedby": "1"}, {"bib": {"title": "ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor\u2013Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uQVPmWFBlwUC", "citedby": "0"}, {"bib": {"title": "Response to J\u00e9z\u00e9quel, Patsouris, Guette, et. al.", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JqN3CTdJtl0C", "citedby": "0"}, {"bib": {"title": "Neurofibromin Is an Estrogen Receptor-\u03b1 Transcriptional Co-repressor in Breast Cancer", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cx97FdCJQX8C", "citedby": "0"}, {"bib": {"title": "Abstract GS2-05: Microscaled proteogenomic methods for precision oncology", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DPO9WFcz7UcC", "citedby": "0"}, {"bib": {"title": "Abstract P6-04-20: Proteogenomic analysis of estrogen modulated breast cancer metastasis", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oYwriLWYh5YC", "citedby": "0"}, {"bib": {"title": "Abstract P6-04-04: Functional characterization of ESR1 fusions in breast cancer", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-fu4zM_6qcIC", "citedby": "0"}, {"bib": {"title": "Abstract P2-16-03: Neoadjuvant treatment of triple negative breast cancer patients with docetaxel and carboplatin to assess anti-tumor activity", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uWy0R8PweswC", "citedby": "0"}, {"bib": {"title": "Abstract TS1-3: Proteogenomics and Clinical Translation", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:EsrhoZGmrkoC", "citedby": "0"}, {"bib": {"title": "Abstract TS1-2: Proteogenomic Landscape of Prospectively Collected Breast Cancer", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1Aeql8wG3wEC", "citedby": "0"}, {"bib": {"title": "Abstract BL2: The Molecular Etiology of Luminal-Type Breast Cancer", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:e9bUPLv0EjcC", "citedby": "0"}, {"bib": {"title": "Abstract PD7-03: Adaptive kinome reprogramming in endocrine therapy resistant metastatic breast cancer", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Lo8V22OuN40C", "citedby": "0"}, {"bib": {"title": "Abstract P2-11-08: ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER-positive breast cancer treated with neoadjuvant endocrine therapy", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tFzHCjejgA0C", "citedby": "0"}, {"bib": {"title": "GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:fF_gHTpLxhAC", "citedby": "0"}, {"bib": {"title": "Local-regional Recurrence (LRR) Following Neoadjuvant Endocrine Therapy (NET): Data from ACOSOG Z1031 (Alliance)", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:10A3hb2jUxYC", "citedby": "0"}, {"bib": {"title": "Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Yw6v6SrDvuUC", "citedby": "0"}, {"bib": {"title": "Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor \u03b1", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9CGX2owmTHMC", "citedby": "0"}, {"bib": {"title": "CDK4/6 inhibitor biomarker research: are we barking up the wrong tree?", "year": "2020"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZqLB7dQ1iF4C", "citedby": "0"}, {"bib": {"title": "Endocrine therapy resistance: new insights", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:w0odbtu79TwC", "citedby": "0"}, {"bib": {"title": "Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JdL-Xu2nR38C", "citedby": "0"}, {"bib": {"title": "Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early \u2026", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yKzB5RS27GgC", "citedby": "0"}, {"bib": {"title": "Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:I2jIoRS3jIgC", "citedby": "0"}, {"bib": {"title": "GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dMpQl7XwOw4C", "citedby": "0"}, {"bib": {"title": "Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:koF6b02d8EEC", "citedby": "0"}, {"bib": {"title": "Identification of differential genes in luminal breast tumors by comparison of Brazilian and American population data", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4tNoA7Af41QC", "citedby": "0"}, {"bib": {"title": "Novel clinical targets revealed by kinome reprogramming in mutant ESR1 metastatic breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KqW5X_olkfQC", "citedby": "0"}, {"bib": {"title": "Functional significance of ESR1 fusions with diverse gene partners in endocrine therapy resistant breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:UarirCmVI0EC", "citedby": "0"}, {"bib": {"title": "Abstract LB-006: Proteogenomic characterization of human colon cancer reveals new therapeutic opportunities", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SPgmg5JLkoEC", "citedby": "0"}, {"bib": {"title": "Concurrent in vitro and in silico approach for the identification of surface proteome targets on HPV-associated cancer cells", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5bfplxN71z4C", "citedby": "0"}, {"bib": {"title": "Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DUFsPKDdMi0C", "citedby": "0"}, {"bib": {"title": "A comprehensive proteogenomic analysis of uterine cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nroGzMJTTpEC", "citedby": "0"}, {"bib": {"title": "Decoding the Luminal Breast Cancer Genome\u2013insights for 2019", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3_f9JqYsqVQC", "citedby": "0"}, {"bib": {"title": "Abstract P6-17-15: Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KsTgnNRry18C", "citedby": "0"}, {"bib": {"title": "Abstract PD6-02: A randomized, controlled trial of high dose vs. standard dose vitamin D for aromatase inhibitor-induced arthralgia in breast cancer survivors", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:h1pkognVyKwC", "citedby": "0"}, {"bib": {"title": "Abstract P1-15-05: Is absolute lymphocyte count associated with platinum-sensitivity? A phase II single arm study evaluating the efficacy of neoadjuvant carboplatin and \u2026", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QtA78RmWg5MC", "citedby": "0"}, {"bib": {"title": "Abstract PD7-08: Immune checkpoint upregulation and T-cell exhaustion in aggressive hormone-receptor positive breast cancer patients", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:g30IDTdgJMgC", "citedby": "0"}, {"bib": {"title": "Abstract P5-08-01: DPYSL3 modulates mitosis, migration and epithelial to mesenchymal transition in claudin-low breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:o-PowTg_VKEC", "citedby": "0"}, {"bib": {"title": "Abstract P5-04-01: Functional and therapeutic significance of ESR1 fusions in metastatic ER+ breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:U3qCfcK-7lkC", "citedby": "0"}, {"bib": {"title": "Abstract P5-04-30: Developing an immunohistochemistry protocol to detect neurofibromin as an effective, simple, and rapid method to identify NF1-negative breast cancer patients", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YGhAHpnIhDoC", "citedby": "0"}, {"bib": {"title": "Abstract P1-06-02: Mismatch repair protein loss in breast cancer: Clinicopathological associations in a large British Columbia cohort", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KIRwYnRZzWQC", "citedby": "0"}, {"bib": {"title": "Abstract P6-15-03: MBC Connect\u2122, an open-access, patient-reported registry of de-identified data from patients living with metastatic breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:s2G-WRnXBicC", "citedby": "0"}, {"bib": {"title": "Immune checkpoint upregulation and T-cell exhaustion in aggressive hormone-receptor positive breast cancer patients", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wlzmIqt2EaEC", "citedby": "0"}, {"bib": {"title": "MBC Connect (TM), an open-access, patient-reported registry of de-identified data from patients living with metastatic breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:gkldIfsazJcC", "citedby": "0"}, {"bib": {"title": "Developing an immunohistochemistry protocol to detect neurofibromin as an effective, simple, and rapid method to identify NF1-negative breast cancer patients", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:6pF0wJmtdfAC", "citedby": "0"}, {"bib": {"title": "Is absolute lymphocyte count associated with platinum-sensitivity? A phase II single arm study evaluating the efficacy of neoadjuvant carboplatin and docetaxel in triple \u2026", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oXKBmVzQOggC", "citedby": "0"}, {"bib": {"title": "Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus \u2026", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oFn-K-OQSCAC", "citedby": "0"}, {"bib": {"title": "Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer", "year": "2019"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RVqaWcrwK10C", "citedby": "0"}, {"bib": {"title": "Direct Regulation of Estrogen Receptor Transcriptional Activity by NF1", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:F9HO9s0W2bwC", "citedby": "0"}, {"bib": {"title": "Abstract B04: CDK4/6 inhibition triggers an antitumor immune response", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:x2hKVfJWtf0C", "citedby": "0"}, {"bib": {"title": "TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer.", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NnTm98qLMbgC", "citedby": "0"}, {"bib": {"title": "Abstract A25: TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:za7pDTvVV8kC", "citedby": "0"}, {"bib": {"title": "NF1 as an estrogen receptor-\u03b1 co-repressor in breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dFKc6_kCK1wC", "citedby": "0"}, {"bib": {"title": "Defects in multiple DNA damage repair pathways render endocrine treatment resistance in ER+ breast cancer patients", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BCdnXsLIVDwC", "citedby": "0"}, {"bib": {"title": "Functional and therapeutic significance of ESR1 gene fusions in breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Ul_CLA4dPeMC", "citedby": "0"}, {"bib": {"title": "Abstract P2-09-19: Genomic biomarker for resistance to palbociclib in the NeoPalAna trial", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cww_0JKUTDwC", "citedby": "0"}, {"bib": {"title": "Abstract P2-02-12: Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GtqhT-R7ZnwC", "citedby": "0"}, {"bib": {"title": "Abstract P4-10-16: Impact of delay in breast cancer diagnosis and treatment in public health according to nationality: Brazil vs US", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tgTmbKTkO1IC", "citedby": "0"}, {"bib": {"title": "Abstract P4-10-15: Impact of delay in breast cancer diagnosis and treatment according to health insurance status in southwest Brazil and Houston, Texas", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1xBWf43XMUgC", "citedby": "0"}, {"bib": {"title": "Abstract P1-01-08: DPYSL3 modulates proliferation and migration in claudin-low breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:xa5BkEQK8BgC", "citedby": "0"}, {"bib": {"title": "Abstract P4-12-04: Cost-effectiveness analysis of locally advanced estrogen receptor-positive, HER-2 negative breast cancer care using a tailored treatment approach in Brazil", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nU66GSXDKhoC", "citedby": "0"}, {"bib": {"title": "Abstract P2-09-16: Tumor infiltrating lymphocytes (TILs) as a biomarker for resistance to palbociclib (Pal) in the NeoPalAna trial", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:urP0JZOBBUsC", "citedby": "0"}, {"bib": {"title": "Abstract P5-06-01: Proteomic analysis of conserved kinases between PDX tumors and corresponding PDX-derived cell lines", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4oJvMfeQlr8C", "citedby": "0"}, {"bib": {"title": "Abstract GS2-01: Discovery and characterization of an estrogen bound LncRNA in late-Stage breast cancer", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:xii_ZKWM4-0C", "citedby": "0"}, {"bib": {"title": "Abstract PD5-09: Fulvestrant for hormone receptor-positive advanced breast cancer in patients with visceral vs non-visceral metastases: Findings from FALCON, FIRST, and CONFIRM", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NXYAu82O0W8C", "citedby": "0"}, {"bib": {"title": "Copy number aberration driven endocrine response gene signature", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:I-2NeQpV75MC", "citedby": "0"}, {"bib": {"title": "Copy number aberration driven endocrine response gene signature", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jgBuDB5drN8C", "citedby": "0"}, {"bib": {"title": "Cost-effectiveness analysis of locally advanced estrogen receptor-positive, HER-2 negative breast cancer care using a tailored treatment approach in Brazil", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:VjBpw8Hezy4C", "citedby": "0"}, {"bib": {"title": "Impact of delay in breast cancer diagnosis and treatment according to health insurance status in southwest Brazil and Houston, Texas", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cF7EPgIk0B4C", "citedby": "0"}, {"bib": {"title": "Lessons for ER plus breast cancer from neoadjuvant endocrine therapy trials", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eAUscmXIlQ8C", "citedby": "0"}, {"bib": {"title": "Abstract IA23: Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials", "year": "2018"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SWgZeABleR0C", "citedby": "0"}, {"bib": {"title": "ABC4 Scientific Committee", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:I9gX6wnfuA8C", "citedby": "0"}, {"bib": {"title": "An interview with Professor Matthew Ellis at the NCRI 2017 Cancer Conference", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oynPyU19kbsC", "citedby": "0"}, {"bib": {"title": "In Vitro Characterization and Clinical Correlation of BRCAness as a Personalized Biomarker for Radiosensitization With Homologous Recombination Directed Therapies", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XeErXHja3Z8C", "citedby": "0"}, {"bib": {"title": "Breast tumors educate stromal tissue with individualized but coordinated proteomic signatures", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jRIwE-1ttnoC", "citedby": "0"}, {"bib": {"title": "Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hKjooKYXoHIC", "citedby": "0"}, {"bib": {"title": "Mismatch repair defects and endocrine therapy resistance in estrogen receptor positive breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vxA22ZmNLkoC", "citedby": "0"}, {"bib": {"title": "\u5982\u4f55\u907f\u514d\u4e73\u817a\u764c\u5185\u5206\u6ccc\u8f85\u52a9\u7597\u6cd5\u7814\u7a76\u5f97\u51fa\u9634\u6027\u7ed3\u679c", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4E1Y8I9HL1wC", "citedby": "0"}, {"bib": {"title": "Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2 \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:pRWBApOjXDcC", "citedby": "0"}, {"bib": {"title": "Method of classifying a breast cancer instrinsic subtype", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hB2aVRuWZNwC", "citedby": "0"}, {"bib": {"title": "Method of classifying a breast cancer instrinsic subtype", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8RAEygVn5_EC", "citedby": "0"}, {"bib": {"title": "Neoadjuvant endocrine therapy\u2013moving forward as a standard of care?", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:S2WlVNSe3u4C", "citedby": "0"}, {"bib": {"title": "Methods and compositions involving intrinsic genes", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DIubQTN3OvUC", "citedby": "0"}, {"bib": {"title": "Abstract P5-04-02: Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:pUxgyZctzPYC", "citedby": "0"}, {"bib": {"title": "Abstract P1-07-11: Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ShjGdcaqzI0C", "citedby": "0"}, {"bib": {"title": "Abstract P5-04-02: Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wBLCggQE-ToC", "citedby": "0"}, {"bib": {"title": "Abstract P1-08-01: Regulation of estrogen receptor-\u03b1 by NF1", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:K4-iKlO5MD4C", "citedby": "0"}, {"bib": {"title": "Abstract P2-08-02: Progression-free survival results in patient subgroups from a Phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BW2nPTmhBn4C", "citedby": "0"}, {"bib": {"title": "Abstract PD2-03: Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wGzT3bKASkAC", "citedby": "0"}, {"bib": {"title": "Abstract P1-08-07: Assessing the impact of loss of NF1 protein on endocrine therapy resistance", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cB__R-XWw9UC", "citedby": "0"}, {"bib": {"title": "Abstract PD2-06: Mismatch repair deficiency induces endocrine therapy resistance in breast cancer", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rFyVMFCKTwsC", "citedby": "0"}, {"bib": {"title": "Progression-free survival results in postmenopausal Asian women: Subgroup analysis from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor \u2026", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9VeumLvkZSQC", "citedby": "0"}, {"bib": {"title": "Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel", "year": "2017"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:BFa5h04uPMwC", "citedby": "0"}, {"bib": {"title": "Abstract IA01: The proteogenomics of breast cancer patient-derived xenografts", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ukw-9cB-YDkC", "citedby": "0"}, {"bib": {"title": "Abstract LB-267: The proteomic landscape of patient-derived breast cancer xenografts reveals tumor-specific differences in the breast tumor microenvironment", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DquSII9TDu4C", "citedby": "0"}, {"bib": {"title": "Abstract CT091: A neoadjuvant co-clinical trial in triple-negative breast cancer patients with genomic discovery analysis", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cNe27ouKFcQC", "citedby": "0"}, {"bib": {"title": "Identification of estrogen receptor alpha 1 bound lncRNAs in aggressive breast cancer", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:V_vSwabWVtYC", "citedby": "0"}, {"bib": {"title": "The proteomic landscape of patient-derived breast cancer xenografts reveals tumor-specific differences in the breast tumor microenvironment", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1_W9tMSvGuwC", "citedby": "0"}, {"bib": {"title": "Gene expression profiles to predict breast cancer outcomes", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:M_lZXyI38BkC", "citedby": "0"}, {"bib": {"title": "Reply to T. Reinert et al", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:H7nrzBkawXsC", "citedby": "0"}, {"bib": {"title": "From the 33rd Annual Miami Breast Cancer Conference", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PuOEWVtPfzwC", "citedby": "0"}, {"bib": {"title": "Different Mechanisms Utilized By Mutant Estrogen Receptor Alpha Proteins to Activate Transcription in a Ligand-Independent Manner", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3A3nxV7CjKIC", "citedby": "0"}, {"bib": {"title": "Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC-> P \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:cOfwuRB03ygC", "citedby": "0"}, {"bib": {"title": "The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer-Results from the ACOSOG Z1041 (Alliance) trial", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GUYAmugLYisC", "citedby": "0"}, {"bib": {"title": "Abstract P5-13-04: A phase II neoadjuvant trial of MK-2206, an AKT inhibitor, in combination with anastrozole for clinical stage 2 or 3 PIK3CA mutant estrogen receptor positive \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Y0-TYkg6YM4C", "citedby": "0"}, {"bib": {"title": "Abstract P5-14-01: A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:FsLZdJ3BAzkC", "citedby": "0"}, {"bib": {"title": "Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rCNdntzdTkkC", "citedby": "0"}, {"bib": {"title": "Abstract P1-14-02: Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by paclitaxel plus \u2026", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Azgs6IHzeyYC", "citedby": "0"}, {"bib": {"title": "Abstract PD6-02: The genomics of response to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer\u2013Results from the ACOSOG Z1041 (Alliance) trial", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KS-xo-ZNxMsC", "citedby": "0"}, {"bib": {"title": "AROMATASE INHIBITOR-INDUCED HORMONE LEVEL CHANGE ASSOCIATED WITH CSMD1 SNP AND ANDROSTENEDIONE-DEPENDENT VARIATION IN AROMATASE EXPRESSION.: PII-038", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:W2uZP3ddy8sC", "citedby": "0"}, {"bib": {"title": "Abstract B30: Ex vivo culture of breast cancer patient-derived xenografts in modified 3-D hyaluronan hydrogels", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:7Frjd3zlGBUC", "citedby": "0"}, {"bib": {"title": "Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors", "year": "2016"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8uzoZH4hB9AC", "citedby": "0"}, {"bib": {"title": "Abstract C200: Effects of PI3K/Akt pathway inhibition on global proteome levels and phosphorylation signaling in patient-derived xenograft models of triple negative breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:7H_jS4BsgvYC", "citedby": "0"}, {"bib": {"title": "Abstract A1-44: Clinical cancer sequencing and integrated analysis of whole genomes, exomes and transcriptomes", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1tZ8xJnm2c8C", "citedby": "0"}, {"bib": {"title": "Abstract A1-06: Recurrent mutations of hormone-positive breast cancer and association with outcome", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ghEM2AJqZyQC", "citedby": "0"}, {"bib": {"title": "ISY3-1Drug sensitivity analysis with PDX models in breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RJOyoaXV5v8C", "citedby": "0"}, {"bib": {"title": "PSY1-1Genome directed therapy for estrogen receptor positive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eGYfIraVYiQC", "citedby": "0"}, {"bib": {"title": "Abstract B19: Associations among race/ethnicity, geography, and breast cancer incidence and mortality in Trinidad and Tobago", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jSAVyFp_754C", "citedby": "0"}, {"bib": {"title": "The molecular profiles of disseminated tumor cells in a Patient Derived Xenograft model recapitulate those found in patient bone marrow", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kJDgFkosVoMC", "citedby": "0"}, {"bib": {"title": "Proteogenomic characterization of breast cancer sub-types in patient derived xenografts", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ALROH1vI_8AC", "citedby": "0"}, {"bib": {"title": "Abstract SY44-02: Proteogenomic and phosphoproteomic analysis of breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:lgwcVrK6X84C", "citedby": "0"}, {"bib": {"title": "Discovery and proteogenomic investigation of genetic variants in human cancers", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:48xauSegjOkC", "citedby": "0"}, {"bib": {"title": "Aromatase inhibition shapes the clonal architecture of estrogen receptor-positive breast cancers", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:buQ7SEKw-1sC", "citedby": "0"}, {"bib": {"title": "Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase \u2026", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uEM9VtRl8xsC", "citedby": "0"}, {"bib": {"title": "Genome-Directed Therapeutics for Endocrine Therapy Resistant ER plus Breast Cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Q3-QASNKTMEC", "citedby": "0"}, {"bib": {"title": "Abstract PD6-4: ESR1 gene fusions implicated in endocrine therapy resistance of ER+ breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DUooU5lO8OsC", "citedby": "0"}, {"bib": {"title": "Abstract P5-10-02: A copy number aberration driven endocrine response gene signature stratifies risk in estrogen receptor positive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HoB7MX3m0LUC", "citedby": "0"}, {"bib": {"title": "Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in \u2026", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:70eg2SAEIzsC", "citedby": "0"}, {"bib": {"title": "Abstract OT2-1-02: A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qUcmZB5y_30C", "citedby": "0"}, {"bib": {"title": "Abstract PL-1: Genome-Directed Therapeutics for Endocrine Therapy Resistant ER+ Breast Cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:M3ejUd6NZC8C", "citedby": "0"}, {"bib": {"title": "Abstract P4-11-11: CADER prognostic gene signature for disease free survival in hormone receptor positive breast cancer: NCIC CTG MA. 12 phase III placebo-controlled tamoxifen \u2026", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IjCSPb-OGe4C", "citedby": "0"}, {"bib": {"title": "Abstract IA03: Mutations, drugs, and breast cancer: How are we going to figure it out?", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YsMSGLbcyi4C", "citedby": "0"}, {"bib": {"title": "Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ynsZFq2pu0MC", "citedby": "0"}, {"bib": {"title": "A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Ei5r6KrKXVQC", "citedby": "0"}, {"bib": {"title": "Prospective Validation of a 21-Gene Expression Assay in Breast Cancer", "year": "2015"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oAywNP-vUhwC", "citedby": "0"}, {"bib": {"title": "Predicting response and survival in chemotherapy-treated triple-negative breast cancer", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eFf2swCANGcC", "citedby": "0"}, {"bib": {"title": "The relationship between body mass index, diabetes, and triple-negative breast cancer prognosis.", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zCSUwVk65WsC", "citedby": "0"}, {"bib": {"title": "Genomic events in breast cancer progression", "year": "2014"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dhpJJ7xvgBgC", "citedby": "0"}, {"bib": {"title": "Patient-derived xenograft study reveals endocrine therapy resistance of ER plus breast cancer caused by distinct ESR1 gene aberrations", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:kvJssbFybhEC", "citedby": "0"}, {"bib": {"title": "A randomized pacebo-controlled phase II trial evaluating the effect of hedgehog inhibitor LDE225 on bone marrow disseminated tumor cells in women with early stage estrogen \u2026", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5F1dSjz1ScoC", "citedby": "0"}, {"bib": {"title": "FALCON: A randomised, double-blind, multicentre, phase III study comparing fulvestrant 500 mg with anastrozole 1 mg for postmenopausal women with hormone receptor-positive \u2026", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:jKT558fuBk8C", "citedby": "0"}, {"bib": {"title": "Abstract OT2-6-12: A randomized pacebo-controlled phase II trial evaluating the effect of hedgehog inhibitor LDE225 on bone marrow disseminated tumor cells in women with early \u2026", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:27LrP4qxOz0C", "citedby": "0"}, {"bib": {"title": "Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial)", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_kc_bZDykSQC", "citedby": "0"}, {"bib": {"title": "Massively parallel sequencing for predictors of therapy", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:P7Ujq4OLJYoC", "citedby": "0"}, {"bib": {"title": "Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:PZE8UkGerEcC", "citedby": "0"}, {"bib": {"title": "Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance.", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ldfaerwXgEUC", "citedby": "0"}, {"bib": {"title": "Abstract LB-236: Patient derived xenografts as high-fidelity genomic models for advanced breast cancer.", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LkGwnXOMwfcC", "citedby": "0"}, {"bib": {"title": "\" Preclinical Clinical Trials\" Using Patient-Derived Xenograft (PDX) Models of Human Breast Cancer in Immunocompromised Mice", "year": "2013"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3MwzVuqRcA0C", "citedby": "0"}, {"bib": {"title": "Abstract P2-04-02: Identification of genes associated with breast cancer micrometastatic disease in bone marrow using a human-in-mouse xenograft system", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DyXnQzXoVgIC", "citedby": "0"}, {"bib": {"title": "Abstract P1-08-01: Effects Of An Allosteric AKT Inhibitor (MK2206) Administered With Or Without The Aromatase Inhibitor Vorozole In An ER+ Rat Mammary Cancer Model: Preventive \u2026", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:roLk4NBRz8UC", "citedby": "0"}, {"bib": {"title": "Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WF5omc3nYNoC", "citedby": "0"}, {"bib": {"title": "BREAST CANCER GENE EXPRESSION ANALYSIS", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1wZ_wKGpLuwC", "citedby": "0"}, {"bib": {"title": "ESMO-ASCO-Genomics in breast cancer: Opening new doors", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IExZWSxeYXUC", "citedby": "0"}, {"bib": {"title": "Whole Genome Sequencing for Luminal-Type Breast Cancer", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9c2xU6iGI7YC", "citedby": "0"}, {"bib": {"title": "Which Luminal BC need Chemotherapy?", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2VqYfGB8ITEC", "citedby": "0"}, {"bib": {"title": "ESMO-ASCO-Genomics in breast cancer: Opening new doors", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:sNmaIFBj_lkC", "citedby": "0"}, {"bib": {"title": "\u533b\u5b66 \u5168\u30b2\u30ce\u30e0\u89e3\u6790\u304b\u3089\u660e\u3089\u304b\u306b\u306a\u3063\u305f, \u30a2\u30ed\u30de\u30bf\u30fc\u30bc\u963b\u5bb3\u3078\u306e\u4e73\u304c\u3093\u306e\u5fdc\u7b54\u6027", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zzCxg_vo7cAC", "citedby": "0"}, {"bib": {"title": "Racial differences in outcomes of triple-negative breast cancer.", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:5LPo_wSKItgC", "citedby": "0"}, {"bib": {"title": "Abstract IA3: PI3K inhibitors in ER+ breast cancer: Next steps", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u-x6o8ySG0sC", "citedby": "0"}, {"bib": {"title": "PI3K inhibitors in ER plus breast cancer: Next steps", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:oH8HCDhqVGsC", "citedby": "0"}, {"bib": {"title": "Inhibition of mTOR and AKT as a potential strategy for the treatment of basal-like breast cancer", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ns9cj8rnVeAC", "citedby": "0"}, {"bib": {"title": "Abstract LB-423: Whole genome comparisons of pre-and post-aromatase inhibitor treatment in estrogen receptor positive breast cancer", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:maZDTaKrznsC", "citedby": "0"}, {"bib": {"title": "Cancer as a Therapeutic Roadmap", "year": "2012"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-38epGy1wY0C", "citedby": "0"}, {"bib": {"title": "MS1-3: Tumor Heterogeneity and Metastasis.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:gKiMpY-AVTkC", "citedby": "0"}, {"bib": {"title": "Response to subsequent endocrine therapy in patients treated with fulvestrant 500mg or anastrozole: results from FIRST", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:pqnbT2bcN3wC", "citedby": "0"}, {"bib": {"title": "Quality assurance review center: Role in multi-institutional breast cancer trials.", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IUKN3-7HHlwC", "citedby": "0"}, {"bib": {"title": "Genome-forward oncology: how do we get there?", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Tyk-4Ss8FVUC", "citedby": "0"}, {"bib": {"title": "Hormone Receptor Positive Breast Cancer resource centre Made possible by an educational grant from AstraZeneca. AstraZeneca has no influence on the content and all items are \u2026", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GHsHDPAyICYC", "citedby": "0"}, {"bib": {"title": "Development of a mouse model for bone marrow disseminated tumor cells with human tumor xenografts", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:g5Ck-dwhA_QC", "citedby": "0"}, {"bib": {"title": "Combination of fulvestrant with the allosteric Akt inhibitor MK-2206 promotes anti-tumor activity in estrogen deprivation-resistant estrogen receptor positive breast cancer", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hFOr9nPyWt4C", "citedby": "0"}, {"bib": {"title": "Abstract LB-327: Analytical performance of the nCounter analysis system for gene expression cancer signatures", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:L8Ckcad2t8MC", "citedby": "0"}, {"bib": {"title": "The 8p11. 2 Amplicon Is Associated with Hormonal Treatment Resistance and a Worse Clinical Outcome: Validation by FISH, aCGH and Gene Expression Profiling", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:OP4eGU-M3BUC", "citedby": "0"}, {"bib": {"title": "Published Ahead of Print on May 9, 2011 as 10.1200/JCO. 2010.31. 6950", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:N6_Y7JlWxwsC", "citedby": "0"}, {"bib": {"title": "Hormonioterapia neoadjuvante no c\u00e2ncer de mama", "year": "2011"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IWHjjKOFINEC", "citedby": "0"}, {"bib": {"title": "Modulating Response to Phosphoinositol-3-Kinase/mTOR Inhibition in ER Positive Breast Cancer Cell Lines after Acquired Resistance to Estrogen Deprivation", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uPCvBZYD9qUC", "citedby": "0"}, {"bib": {"title": "Abstract ES7-1: Next Generation Sequencing for the Clinician: A Breast Cancer Study", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vDZJ-YLwNdEC", "citedby": "0"}, {"bib": {"title": "Abstract P2-19-01: Modulating Response to Phosphoinositol-3-Kinase/mTOR Inhibition in ER Positive Breast Cancer Cell Lines after Acquired Resistance to Estrogen Deprivation", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:JV2RwH3_ST0C", "citedby": "0"}, {"bib": {"title": "Abstract P2-09-16: Effect of Continuous Statistically Standardized qPCR and IHC ER and PR on Disease-Free Survival in NCIC CTG MA. 12", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9yKSN-GCB0IC", "citedby": "0"}, {"bib": {"title": "243 Targeting the Chk1/Cdc25A pathway in p53-deficient tumors", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_OXeSy2IsFwC", "citedby": "0"}, {"bib": {"title": "Epidemiology of unintentional injuries in children in South East Asian countries: A systematic review", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:WC23djZS0W4C", "citedby": "0"}, {"bib": {"title": "Massive parallel sequencing of an African-American basal-like breast cancer: Comparison of primary tumor, metastasis, and xenograft.", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:fFSKOagxvKUC", "citedby": "0"}, {"bib": {"title": "Response to phosphoinositol-3-kinase inhibition in ER-positive breast cancer cell lines after acquired resistance to estrogen deprivation.", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:isC4tDSrTZIC", "citedby": "0"}, {"bib": {"title": "Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors", "year": "2010"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Ehil0879vHcC", "citedby": "0"}, {"bib": {"title": "Phosphoinositide-3-Kinase Catalytic Subunit Inhibition Does Not Produce Synthetic Lethality in Estrogen Receptor Positive Breast Cancer Cells with Acquired Resistance to \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZHo1McVdvXMC", "citedby": "0"}, {"bib": {"title": "Prognostic and Predictive Impact of Intrinsic Biological Classification by Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in Pre-Menopausal Breast Cancer: Results \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:9ZlFYXVOiuMC", "citedby": "0"}, {"bib": {"title": "5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dAp6zn-oMfAC", "citedby": "0"}, {"bib": {"title": "5072 Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:eQOLeE2rZwMC", "citedby": "0"}, {"bib": {"title": "Development of Rational Drug Combinations with Investigational Targeted Agents", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:umqufdRvDiIC", "citedby": "0"}, {"bib": {"title": "PIK3CA mutation analysis in recurrent breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8d8msizDQcsC", "citedby": "0"}, {"bib": {"title": "Chronic Kidney Disease After Hematopoietic Cell Transplantation: A Systematic Review.(vol 8, pg 2378, 2008)", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:An6A6Jpfc1oC", "citedby": "0"}, {"bib": {"title": "0185 High-dose fulvestrant (500 mg): Clinical evidence supporting potentially improved efficacy benefits in hormone receptor-positive (HR+) advanced breast cancer (ABC)", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RtRctb2lSbAC", "citedby": "0"}, {"bib": {"title": "Liebert Librarian Resource Center", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:iKswqCX-FLkC", "citedby": "0"}, {"bib": {"title": "A comparative genomic analysis between human breast cancer and paired tumor lines derived from transplanation of tumor biopsies into NOD/SCID mice.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YlPif8NxrbYC", "citedby": "0"}, {"bib": {"title": "A multi-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8xutWZnSdmoC", "citedby": "0"}, {"bib": {"title": "A mufti-center phase II study of three doses of TAS-108 in postmenopausal women with advanced breast carcinoma following first or second line endocrine therapy.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KbBQZpvPDL4C", "citedby": "0"}, {"bib": {"title": "Synthetic lethality when combining phosphoinositide 3-kinase alpha and beta catalytic subunit-directed RNAi and estrogen deprivation for estrogen receptor positive breast \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QIV2ME_5wuYC", "citedby": "0"}, {"bib": {"title": "5080 Safety and tolerability of fulvestrant high-dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:k8to_Y4Q4_EC", "citedby": "0"}, {"bib": {"title": "Neoadjuvant Endocrine Therapy for Breast Cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:rzmi0EmCOGEC", "citedby": "0"}, {"bib": {"title": "Airway Monitoring during Bronchodilation Using Acoustic Transmission Methods.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:w1MjKQ0l0TYC", "citedby": "0"}, {"bib": {"title": "Early Inhomogeneity of Conductive Ventilation Post Lung Transplant Is Associated with Lung Repair.", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:O0nohqN1r9EC", "citedby": "0"}, {"bib": {"title": "Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research \u2026", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:GFxP56DSvIMC", "citedby": "0"}, {"bib": {"title": "Neoadjuvant Endocrine Therapy for Breast Cancer", "year": "2009"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:TFP_iSt0sucC", "citedby": "0"}, {"bib": {"title": "Outcome Predictions for ER+ Breast Cancer Based on Post Neoadjuvant Endocrine Therapy Tumor Profiling", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:XvxMoLDsR5gC", "citedby": "0"}, {"bib": {"title": "Current and Future Roles of Lapatinib in HER2-Positive Breast Cancer", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:It0W0vAlS5QC", "citedby": "0"}, {"bib": {"title": "The A Allele at Valine80 of the CYP19 Gene Is a Risk factor for Aromatase Inhibitors Associated Bone Loss", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:u5HHmVD_uO8C", "citedby": "0"}, {"bib": {"title": "Human and mouse linked evaluation of tumors", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:X9ykpCP0fEIC", "citedby": "0"}, {"bib": {"title": "Proliferative rate variability and distribution in breast cancer: Implications for assessment in tissue microarrays", "year": "2008"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:blknAaTinKkC", "citedby": "0"}, {"bib": {"title": "What have we gained from the application of biological \u2018rationales\u2019?", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3s1wT3WcHBgC", "citedby": "0"}, {"bib": {"title": "Prevalence of vitamin D insufficiency in patients with breast cancer", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Y0pCki6q_DkC", "citedby": "0"}, {"bib": {"title": "The academic oncology hospitalist\u2014a model for improved teaching and patient care", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mVmsd5A6BfQC", "citedby": "0"}, {"bib": {"title": "Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:anf4URPfarAC", "citedby": "0"}, {"bib": {"title": "Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:0aBXIfxlw9sC", "citedby": "0"}, {"bib": {"title": "Tamoxifen Treatment After Adjuvant Chemotherapy has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:a3BOlSfXSfwC", "citedby": "0"}, {"bib": {"title": "Ocular Toxicity During Adjuvant Chemoendocrine Therapy for Early Breast Cancer: Results From International Breast Cancer Study Group Trials", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:DJbcl8HfkQkC", "citedby": "0"}, {"bib": {"title": "Single sample prediction of breast cancer biological subtypes from formalin-fixed paraffin-embedded tissue using real-time quantitative RT-PCR", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:HDshCWvjkbEC", "citedby": "0"}, {"bib": {"title": "Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Commentary", "year": "2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:MXK_kJrjxJIC", "citedby": "0"}, {"bib": {"title": "Proceedings of the Satellite Symposium-'The quiet revolution in breast cancer treatment: how aromatase inhibitors are displacing tamoxifen'at ECCO 13, 30 October 2005, Paris \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_FxGoFyzp5QC", "citedby": "0"}, {"bib": {"title": "Pathology Parameters and Adjuvant Tamoxifen Response in a Randomised Premenopausal Breast Cancer Trial", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Aul-kAQHnToC", "citedby": "0"}, {"bib": {"title": "Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel (Taxoprexin) in resistant solid tumor malignancies", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3vbIHxFL9FgC", "citedby": "0"}, {"bib": {"title": "Phase I and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel (Taxoprexin) in resistant solid tumor malignancies.", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:naSTrk-c4S8C", "citedby": "0"}, {"bib": {"title": "Original Reports", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:17ZO-CJnx_8C", "citedby": "0"}, {"bib": {"title": "trials clinical", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yY3RG6sOEgwC", "citedby": "0"}, {"bib": {"title": "Z. Hu, C. Fan, Daniel S. Oh, JS Marron, X. He, BF Qaqish, G. Karaca, C. Livasy, LA Carey, E. Reynolds, L. Dressler, A. Nobel, J. Parker, MG Ewend, LR Sawyer, D. Xiang, J. Wu, Y \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:QAOzB4mb83kC", "citedby": "0"}, {"bib": {"title": "The members of the Editorial Board and the following referees have assisted the Editors and Publisher in preparing the 2005 volumes of Breast Cancer Research and Treatment \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:tH6gc1N1XXoC", "citedby": "0"}, {"bib": {"title": "Phase II Study of Sequential Hormonal Therapy With Anastrozole/Exemestane in Advanced and Metastatic Breast Cancer", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:fbc8zXXH2BUC", "citedby": "0"}, {"bib": {"title": "3\u201351 A Meta-Analysis on the Interaction Between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:r_AWSJRzSzQC", "citedby": "0"}, {"bib": {"title": "Can Molecular Markers Predict When to Implement Treatment With Aromatase Inhibitors in Invasive Breast Cancer?", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4vMrXwiscB8C", "citedby": "0"}, {"bib": {"title": "A response to high-dose estrogen for tamoxifen, aromatase inhibitor and trastuzumab refractory HER2+ and ER+ advanced breast cancer", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:a9-T7VOCCH8C", "citedby": "0"}, {"bib": {"title": "Identification of Biomarker Candidate, Catechol Estrogen-DNA Adduct, in Human Breast Tissue", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YFjsv_pBGBYC", "citedby": "0"}, {"bib": {"title": "Original Reports-BREAST CANCER-Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mB3voiENLucC", "citedby": "0"}, {"bib": {"title": "The Quiet Revolution in Breast Cancer Treatment: Proceedings of the Satellite Symposium The Quiet Revolution in Breast Cancer Treatment: how Aromatase Inhibitors are Displacing \u2026", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Zph67rFs4hoC", "citedby": "0"}, {"bib": {"title": "Metastatic Breast Cancer: Tailored Endocrine Therapy for Postmenopausal Women", "year": "2006"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qjMakFHDy7sC", "citedby": "0"}, {"bib": {"title": "A pharmacokinetic and pharmacodynamic Phase 1 study of UCN-01 and irinotecan in resistant solid tumors.", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zUl2_INMlC4C", "citedby": "0"}, {"bib": {"title": "Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342.", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:wuD5JclIwkYC", "citedby": "0"}, {"bib": {"title": "Erratum: The PIK3CA gene is mutated with high frequency in human breast cancers (Cancer Biology and Therapy (2004) 3 (772-775))", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:uoRD4RTSUPoC", "citedby": "0"}, {"bib": {"title": "Application of clinico-genomic models that predict breast cancer characteristics in a prospective study", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NXb4pA-qfm4C", "citedby": "0"}, {"bib": {"title": "Original Reports-PREDICTIVE BIOMARKERS/TRANSLATIONAL RESEARCH-Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4fGpz3EwCPoC", "citedby": "0"}, {"bib": {"title": "Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:SeFeTyx0c_EC", "citedby": "0"}, {"bib": {"title": "Original Reports-MOLECULAR ONCOLOGY-Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:lSLTfruPkqcC", "citedby": "0"}, {"bib": {"title": "Chapter 18: Surrogate Biomarkers and Neoadjuvant Endocrine Therapy", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:NaGl4SEjCO4C", "citedby": "0"}, {"bib": {"title": "1\u201344 Late Follow-up of a Randomized Trial of Surgery Plus Tamoxifen Versus Tamoxifen Alone in Women Aged Over 70 Years With Operable Breast Cancer", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:O3NaXMp0MMsC", "citedby": "0"}, {"bib": {"title": "Synergistic Interactions Between Tamoxifen and Trastuzumab (Herceptin)", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:-f6ydRqryjwC", "citedby": "0"}, {"bib": {"title": "3\u201335 HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:8k81kl-MbHgC", "citedby": "0"}, {"bib": {"title": "The Impact of Hormone Receptor Status on the Clinical Efficacy of the New-Generation Aromatase Inhibitors: A Review of Data From First-Line Metastatic Disease Trials in \u2026", "year": "2005"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:UebtZRa9Y70C", "citedby": "0"}, {"bib": {"title": "Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional trial 509", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:FQ36aI_S1AEC", "citedby": "0"}, {"bib": {"title": "Surrogate Biomarkers and Neoadjuvant Endocrine Therapy", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:xGWFX6Gbr9MC", "citedby": "0"}, {"bib": {"title": "Surrogate Biomarkers and Neoadjuvant Endocrine Therapy", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:4hFrxpcac9AC", "citedby": "0"}, {"bib": {"title": "Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials", "year": "2004"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:s1ouQE5r0WUC", "citedby": "0"}, {"bib": {"title": "ORIGINAL REPORTS-Breast Cancer-Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical \u2026", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qPeb-qHga9sC", "citedby": "0"}, {"bib": {"title": "Development of a novel tissue acquisition protocol for biomarker studies in early stage breast cancer", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:YOwf2qJgpHMC", "citedby": "0"}, {"bib": {"title": "Aromatase Inhibitors as Adjuvant Therapy in Breast Cancer The Article Reviewed", "year": "2003"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Se3iqnhoufwC", "citedby": "0"}, {"bib": {"title": "A comparison study of F-18-labeled choline versus F-18-labeled 2-deoxyglucose positron emission tomography for evaluation of advanced breast cancer.", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Nw_I7GeUguwC", "citedby": "0"}, {"bib": {"title": "Neoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist\u2019s Perspective", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:g5m5HwL7SMYC", "citedby": "0"}, {"bib": {"title": "Molecular Oncology, Markers, Clinical Correlates-Development and Validation of a Method for Using Breast Core Needle Biopsies for Gene Expression Microarray Analyses.", "year": "2002"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:aqlVkmm33-oC", "citedby": "0"}, {"bib": {"title": "Neoadjuvant letrozole effective in postmenopausal breast cancer", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:gVv57TyPmFsC", "citedby": "0"}, {"bib": {"title": "Future direction panel discussion", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:mJbmKSuM8toC", "citedby": "0"}, {"bib": {"title": "Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer-Future Use of Selective Estrogen Receptor \u2026", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:0izLItjtcgwC", "citedby": "0"}, {"bib": {"title": "\u041c\u0415\u0414\u0418\u0426\u0418\u041d\u0421\u041a\u0418\u0415 \u0416\u0423\u0420\u041d\u0410\u041b\u042b: JOURNAL OF CLINICAL ONCOLOGY", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:dhFuZR0502QC", "citedby": "0"}, {"bib": {"title": "Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer-Neoadjuvant Endocrine Therapy for Breast \u2026", "year": "2001"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:2osOgNQ5qMEC", "citedby": "0"}, {"bib": {"title": "Stromal Insulin-Like Growth Factor 2 Is a Favorable Prognostic Marker for Breast Cancer, Modified by Age, Estrogen Receptor and Mannose 6-Phosphate/Insulin-Like Growth Factor 2 \u2026", "year": "2000"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RuPIJ_LgqDgC", "citedby": "0"}, {"bib": {"title": "Role of Bone Sialoproteins in Osseous Metastasis of Breast Cancer", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:Ic1VZgkJnDsC", "citedby": "0"}, {"bib": {"title": "Mounting Evidence for Postmastectomy Locoregional Radiation Therapy by Lawrence B. Marks, MD, Patricia Hardenbergh, MD and Leonard R. Prosnitz, MD", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ovGv7akYl-cC", "citedby": "0"}, {"bib": {"title": "The Article Reviewed: Mounting Evidence for Postmastectomy Locoregional Radiation Therapy", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ybfzIt2tCtgC", "citedby": "0"}, {"bib": {"title": "Regular Articles-Experimental Therapeutics-Activation of the Transforming Growth Factor b Signaling Pathway and Induction of Cytostasis and Apoptosis in Mammary Carcinomas \u2026", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ZeXyd9-uunAC", "citedby": "0"}, {"bib": {"title": "The Article Reviewed: Mounting Evidence for Postmastectomy Locoregional Radiation Therapy", "year": "1999"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:zYLM7Y9cAGgC", "citedby": "0"}, {"bib": {"title": "2858 JAMA, June 7, 2000\u2014Vol 283, No. 21 (Reprinted)\u00a9 2000 American Medical Association. All rights reserved.", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:R-LXmdHK_14C", "citedby": "0"}, {"bib": {"title": "Agnarsson BA 12] Arteaga CL 57", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:nqdriD65xNoC", "citedby": "0"}, {"bib": {"title": "ADVANCES IN ENDOCRINE THERAPY FOR BREAST CANCER", "year": "1998"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LO7wyVUgiFcC", "citedby": "0"}, {"bib": {"title": "Metastatic bone disease and the role of bisphosphonates", "year": "1996"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LhH-TYMQEocC", "citedby": "0"}, {"bib": {"title": "THE IGF-II MANNOSE 6-PHOSPHATE RECEPTOR NEGATIVELY REGULATES IGF-II SIGNALING IN BREAST-CANCER CELLS", "year": "1995"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ijdKiLOsEJMC", "citedby": "0"}, {"bib": {"title": "Endocrine therapy of breast cancer IV: A Goldhirsch (Ed) 1990. Springer-Verlag. pp 97\u00a3 24.50 ISBN 3540 529616", "year": "1993"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:KTwcwpFFj4wC", "citedby": "0"}, {"bib": {"title": "Breast lumps and lymphoma.", "year": "1985"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:RHpTSmoSYBkC", "citedby": "0"}, {"bib": {"title": "Tom\u00e1s Reinert*, Susana Ramalho 4, Vivian Castro Antunes de Vasconcelos4"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:LlXTz_FrCmAC", "citedby": "0"}, {"bib": {"title": "Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Sur vival Analysis From the Phase II FIRST Study."}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:e0LTWoPxLYMC", "citedby": "0"}, {"bib": {"title": "CADENCE: Carboplatin And Docetaxel in Neoadjuvant Treatment of ER Negative, HER2 Negative Breast Cancer"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:bbjcffOLshcC", "citedby": "0"}, {"bib": {"title": "Microscaled Cancer Proteogenomics, Progress and Barriers to Clinical Translation"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:qSd0DAb9jMoC", "citedby": "0"}, {"bib": {"title": "Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vD2iS2Kej30C", "citedby": "0"}, {"bib": {"title": "Hormonal Therapy of Breast Cancer"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:yZoBfgUKqwcC", "citedby": "0"}, {"bib": {"title": "Advances and Future Directions in Endocrine Therapy for Breast Cancer: Summary Consensus Statement"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ujxm2eEBZHIC", "citedby": "0"}, {"bib": {"title": "Speakers Overview"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:IT1MJ6E3JesC", "citedby": "0"}, {"bib": {"title": "Supporting Information: Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:MGPUR4WVBMEC", "citedby": "0"}, {"bib": {"title": "http://jnci. oxfordjournals. org"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:3BvdIg-l-ZAC", "citedby": "0"}, {"bib": {"title": "Combined Targeting of mTOR and AKT is an Effective Strategy for Basal-like Breast Cancer in"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:VnuxuLaQPLMC", "citedby": "0"}, {"bib": {"title": "the Nci Cptac, and National Cancer Institute Clinical Proteomics Tumor Analysis Consortium. 2014, Proteogenomic characterization of human colon and rectal cancer"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:1EqfMoDn7-AC", "citedby": "0"}, {"bib": {"title": "Serum Thymidine Kinase 1 Activity as a Pharmacodynamics Marker of Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Early Stage Breast Cancer Receiving Neoadjuvant \u2026"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:T8_be82Iz5gC", "citedby": "0"}, {"bib": {"title": "Article amendments"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:G36d5HCDkJYC", "citedby": "0"}, {"bib": {"title": "SUPPLEMENTARY DOCUMENTS"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:hefNtdE4IMkC", "citedby": "0"}, {"bib": {"title": "Datos Bibliogr\u00e1ficos"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vVJNg6_NJEsC", "citedby": "0"}, {"bib": {"title": "Part 1: Advances in our Understanding of Resistance to Trastuzumab Part 2: An Update on Adjuvant Therapy with Trastuzumab Part 3: An Update on the Use of Lapatinib Part 4: New \u2026"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:M05iB0D1s5AC", "citedby": "0"}, {"bib": {"title": "Breast Cancer Whole Genome Sequencing"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:vV6vV6tmYwMC", "citedby": "0"}, {"bib": {"title": "150702: CORRELATIVE SCIENCE STUDIES FOR CALGB 40601"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:j3f4tGmQtD8C", "citedby": "0"}, {"bib": {"title": "CANCER AND LEUKEMIA GROUP B CALGB 40503/CTSU 40503 ENDOCRINE THERAPY WITH OR WITHOUT ANTI-VEGF THERAPY: A RANDOMIZED, PHASE III TRIAL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE \u2026"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:_Qo2XoVZTnwC", "citedby": "0"}, {"bib": {"title": "S10 EACR-23 Oral Presentations, Sunday 6 July 2014/European Journal of Cancer 50, Suppl. 5 (2014) S3\u2013S11"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:ULOm3_A8WrAC", "citedby": "0"}, {"bib": {"title": "Breast cancer research and treatment Volume: 105 Suppl 1 ISSN: 0167-6806 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 2007"}, "source": "citations", "id_citations": "k9B2zgsAAAAJ:0EnyYjriUFMC", "citedby": "0"}]}